Blood biomarkers for respiratory infections

ABSTRACT

Methods and kits for diagnosing and/or treating a lower respiratory infection in a subject include obtaining a biological sample from the subject; detecting RNA expression levels of one or more biomarkers in the biological sample and comparing the expression levels of the one or more three biomarkers to at least one invariant control marker wherein an increase or decrease in the level of expression of the one or more biomarkers as compared to the at least one invariant control marker is indicative of a lower respiratory infection.

CROSS-REFERENCE OF RELATED APPLICATION

This application claims priority to U.S. Provisional Application No. 62/102,350 filed Jan. 12, 2015, the entire contents of which are hereby incorporated by reference.

BACKGROUND Technical Field

The field of the currently claimed embodiments of this invention relate to methods and kits for assessing and treating lower respiratory infections in a subject, and more particularly to assessing and treating lower respiratory infections in a subject using the analysis of biomarkers isolated from the subject.

Discussion of Related Art

Worldwide, communicable diseases account for 10 million deaths per year [1J. An important step in controlling this problem is developing simple, inexpensive, and rapid diagnostics. Attempts to develop assays based on circulating biomarkers for infection or inflammation in plasma have been largely unsuccessful A major weakness in tills approach is that the key biomarkers are retained within the activated immune cells, particularly primed or activated neutrophils.

Of the 10 million deaths from communicable diseases, the largest category are lower respiratory infections (LRI), such as influenza, and pneumonia, accounting, for 2.8 M deaths per year [1]. By comparison, H1V-related diseases are a close second, with 2.6 M, but diarrheal diseases cause half as many deaths (1.4 M). StHprisingly, fever and elevated white blood cell count (WBC) are very poor metrics of pneumonia. Fever, for in stance, does not occur when an infection is highly localized from the immune system, as occurs in encapsulated lung infections, such as TB. Likewise, other bacteria can form ‘hiofilms’ in which they fuse together (i.e. fusobacteria), and secrete viscous protective coatings that can hinder immune cell response and antibiotic penetration. Further, fever is easily masked by anti-inflammatory medications such as aspirin. Importantly, even if present, fever and elevated WBC do not detect whether the person has a viral versus bacterial infection, a critical factor in the decision whether b use antibiotics or not. In developing countries, and even in rural areas of developed countries, access to imaging equipment, such as X-ray or computed tomography (CT), can be limited. Often, a stethoscope is the only available means to diagnose pulmonary dysfunction, but it has limited ability to distinguish infections from allergy, asthma, or bronchitis and depends primarily on the clinical skills and knowledge of the healthcare personnel,

There is a medical need for a high sensitivity test for infections. There is a growing list of diagnostics that detect specific infections, such as streptococci, sometimes at the point of care. Surprisingly however, there are no commercial blood tests that accurately detect infections in a general way, which could then be used to justify tests for specific pathogens. Recent studies, have described a method for using next-generation sequencing (NGS) to specifically identify the pathogens within a sample of sputum from intubated ICU patients [2], However, it costs >$300 per test arid takes days, without actually knowing whether the patient has a bacterial infection versus bronchial inflammation. Thus, there is a great need for a highly sensitive, but pathogen-agnostic test for internal infections of, for example, the lungs, appendix, central nervous system (CNS), kidneys, and other organs. Once a test is positive, then it is worthwhile to identify the pathogen, whether viral or bacterial, and determine its antibiotic sensitivity.

SUMMARY

Embodiments of the present invention include a method of diagnosing a lower respiratory infection in a subject, including the steps; obtaining a biological sample from the subject; detecting expression levels of one or more biomarkers in the biological sample selected from the group consisting of Neutrophil defensin 1 precursor, Defensin alpha 1, LOC6536G0, defensin alpha IB, Src homology 2 domain containing transforming protein 3, myeloperoxidase, lipocalin 2, cathepsin G, bactericidal/permeability-increasing protein, lactotransferrin (LTF), solute carrier family 22 member 2, methyltrarssferase like 7B, resistin. zinc finger protein 90, family with sequence similarity 46 member C, solute carrier family 7 member 5, aminolevulinate delta-synthase 2, 5′-nucieotidase domain containing 2, LOC646021, G antigen 12F, LOC100133Q75, hypothetical protein FLJ23865, RST17329 Athersys RAGE Library cDNA, hypothetical protein LOC339047 transcript variant 74, CD40 molecule TNF receptor superfamily member 5 transcript variant 2, splicing factor 1 transcript variant 4, synaptophysin-like 1 transcript variant 1, selenoprotein P plasma 1 transcript variant. 1, cDNA DKFZp779F041 1, LOC643Q37, SH3-domain GRB2-like (endophilin) interacting protein 1, microRNA 940, PR domain containing 12′, IMAGE clone 15667343, LOC100128771, i.OC?323871, region containing hypothetical protein LOC283970 transcript variant 2 LOC643943, hypothetical protein LQCI001297Q5, LOC728522, regulator of G-protein signaling 20 transcript variant 1, kelch domain containing 1, LOCI 00134669, tripartite motif-containing 34 transcript variant 2, ribosomal protein LlO-like, LOC100129929, LOC402377, LOC642073, zinc finger protein 461, creatine kinase mitochondrial IB, yy43f04.s1 Soares melanocyte 2NbHM cDNA clone, KIAA1045, ZNF788, primary neuroblastoma clone Nbla10527, processing of precursor 5 ribonuclease P/MRP subunit transcript variant 2, myelin transcription factor 1-like, neuroblastoma breakpoint: family member 7 phosphoKpase C-lifce 1, LOC39 176 1, LOC646498, solute carrier family 7 member 6 transcript variant 2, LOCI 00134648, neuroblastoma breakpoint family member 1 transcript variant 16, absent in melanoma 1-like, EPS8-hke 2, angiopoietin-like 6, LOC645743, V-set and transmembrane domain containing 2A, chemokine binding protein 2, LOC647121, family with sequence similarity 19 (chemokine (C-C motif)-like) member A2, gamma-glutamyltransferase light chain 1 transcript variant A, LOC439949, LOC653157, neurotrophin 3, LOC649686, zinc finger protein 830 (ZNF830), glycerol kinase 5, leueme-rieh repeat-containing G protein receptor 6 transcript variant 3, small nucleolar RNA C/D box 13, cDNA FLJ1 1554 lis clone HEMBA1003037, zinc finger protein 485; and determining the expression levels of the one or more biomarkers by comparing the expression levels of the at least one or more biomarkers to at least one invariant control marker wherein an increase or decrease in the level of expression of one or more biomarkers as compared to the at least one invariant control marker is indicative of a lower respiratory infection.

Embodiments of the present invention include a method of treating a lower respiratory infection in a subject, including the steps of: obtaining a biological sample from the subject; detecting expression levels of one or more biomarkers in the biological sample selected from the group consisting of Neutrophil defensin 1 precursor, Defensin alpha 1, LOC65360G, defensin alpha 1B, Src homology 2 domain containing transforming protein 3, myeloperoxidase, Upocalin 2, cathepsin G, bactericidaj/peiineabiiity-increasing protein{circumflex over ( )} lacMransferrin (LTF), solute carrier family 22 member 2, methyltransferase like 7B, resistin, zinc finger protein 90, family with sequence similarity 46 member C, solute carrier family 7 member 5, aminolevulinate delta-synthase 2, 5′-nucleotidase domain containing 2, LOC646021, G antigen 12F, LOCI 00133075, hypothetical protein FLJ23865, RST17329 Athersys RAGE Library cDNA, hypothetical protein LOC339047 transcript variant 74 CD40 molecule INF receptor superfamily member 5 transcript variant 2, splicing factor 1 transcript variant 4. synaptophysin-Hke 1 transcript variant 1, selenoprotein P plasma 1 transcript variant 1, cDNA DKFZp779F041 1, LOC643037, SH3-domain GRB2-like (endophilin) interacting protein 1, microRNA 940, PR domain containing 12, IMAGE clone 15667343, LOC10012877L LOC732387, region containing hypothetical protein LOC283970 transcript variant 2 LOC643943, hypothetical protein LOC100129705, LOC728522, regulator of G-protein signaling 20 transcript variant 1, kelch domain containing 1, LQC1Q0134669, tripartite motif-containing 34 transcript variant 2, ribosomal protein L10-like, LOC100129929, LOC402377, LOC642073, zinc finger protein 461, creatine kinase mitochondrial IB, yy43f04.s1 Soeres melanocyte 2NbHM cDNA clone, KIAA 1045, ZNF788, primary neuroblastoma clone:Nblal 0527, processing of precursor 5 ribonuclease P/MRP subunit transcript variant 2, myelin transcription factor 1-like, neuroblastoma breakpoint family member 7, phospholipase C-like 1, LOC391761, LOC646498, solute carrier family 7 member 6 transcript variant 2, LOCI 00134648, neuroblastoma breakpoint family member 1 transcript variant 16, absent in melanoma 1-like, EPS8-like 2, angiopoietin-like 6, LOC645743, V-set and transmembrane domain containing 2A, chemokine binding protein 2, LOC647121, family with sequence similarity 19 (chemokine (C-C motif}-like) member A2, gamma-glutamyl transferase light chain 1 transcript variant A, LOC439949, LOC653157, neurotrophin 3, LOC649686, zinc finger protein 830 (ZNF83G), glycerol kinase 5, leucine-rich repeat-containing G protein receptor 6 transcript variant 3, small nucleolar RNA C/D box 13, cDNA FLJ11554 f₁s clone HEMBA1003037, zinc finger protein 485; determining an increase or decrease in the expression levels of said one or more biomarkers by comparing the expression levels of said one or more biomarkers to at least one invariant control marker wherein an increase or decrease of at least three-fold in, the level of expression of said at one or more biomarkers as compared to the at least one invariant control marker is indicative of a lower respiratory infection; and treating the subject for a lower respiratory infection,

Embodiments of the present invention include a kit for use in diagnosing a lower respiratory infection in a subject comprising: agents that specifically bind one or more biomarkers selected from the group consisting of Neutrophil defeatism 1 precursor, Defensin alpha 1, LOC653600, defensin alpha IB, Src homology 2 domain containing transforming protein 3, myeloperoxidase, lipocalin 2, cathepsin G, bacterieidal/permeability-increasing protein, lactotransferrin (LTF), solute carrier family 22 member 2, methyl transferase like 7B, resistin, zinc finger protein 90, family with sequence similarity 46 member C, solute carrier family 7 member 5, aminolevulinate delta-synthase 2, 5′-nucleotidase domain containing 2, LQC646021, G antigen 12F, LOC 100133075, hypothetical protein FLJ23865, RST 17329 Athersys RAGE Library cDNA, hypothetical protein LOC339047 transcript variant 74, CD40 molecule TNF receptor superfamily member 5 transcript variant 2, splicing factor 1 transcript variant 4, syaaptophysin-like 1 transcript variant, selenoprotein P plasma 1 transcript variant 1, cDNA DKFZp779F0411, LOC643037, SH3-domain GRB2-like (endophilin) interacting protein 1, microRNA 940, PR domain containing 12, IMAGE clone 15667343, LOC100128771, LOC732387, region containing, hypothetical protein LOC283970 transcript variant 2 LOC643943, hypothetical protein LOCI 001 29705, LOC728522, regulator of G-protein signaling 20 transcript variant 1, kelch domain containing I, LOG 100 134669, tripaitite motif-containing 34 transcript variant 2, ribosoraal protein 1,10-like, LOCI 00 129929, LOC402377, LOC642073, zinc finger protein 461, creatine kinase mitochondrial 1B, yy43f04.si Soares melanocyte 2NbHM cDNA clone, KIAA 1045, ZNF788, primary neuroblastoma clone:Nblal0527. processing of precursor 5 ribonuclease P/MRP subunit transcript variant 2, myelin transcription factor 1-like, neuroblastoma breakpoint family member 1, phospholipase C-like LOC391761, LOC646498, solute carrier family 7 member 6 transcript variant 2, LQC100134648, neuroblastoma breakpoint family member 1 transcript variant 16, absent in melanoma 1-like, EPS8-like 2, angiopoietin-like 6, LOC645743, V-set and transmembrane domain containing 2A, chemoldne binding protein 2, LOC647121, family with sequence similarity 19 (ehemokine (C-C motif)-like) member A2, gamma-glutamyltransferase light chain 1 transcript variant A, LOC439949, LOC653157, neurotrophin 3, LOC649686, zinc finger protein 830 (ZNF830), glycerol kinase 5, leucine-rich repeat-containing G protein receptor 6 transcript variant 3, small nucleolar RNA C/D box 13, cDNA FLJ11554 fis clone HEMBA1003037, zinc finger protein 485; agents that specifically bind to at least one invariant control marker; a container for housing said agents; and instructions for use of the agents for determining an increase or decrease in the expression levels of said one or more biomarkers by comparing the expression levels of said one or more biomarkers to said at least one invariant control marker wherein an increase or decrease in the level of expression of said one or mote biomarkers as compared to the at, least one invariant control marker is indicative of a lower respiratory infection. In such embodiments, the agents that bind to the biomarkers and/or the invariant control marker bind to nucleotide residues or versions and/or to peptide versions, motifs or residues or amino acid residues of the biomarkers and invariant control marker,

Embodiments of the present invention include a method of diagnosing a lower respiratory infection in a subject comprising: obtaining a biological sample from said subject; and contacting the biological sample from said subject with a kit for use in diagnosing a lower respiratory infection in a subject.

Embodiments of the present invention include a method of treating a lower respiratory infection in a subject comprising: obtaining a biological sample from said subject; contacting the biological sample from said subject with a kit for use in diagnosing a lower respiratory infection in a subject; and treating the subject for a lower respiratory infection by administering antibiotics to said subject, administering antivirals to said subject, administering anti¬inflammatories to said subject, or a combination thereof,

BRIEF DESCRIPTION OF THE DRAWINGS

Further objectives and advantages will become apparent from a consideration of the description, drawings, and examples.

FIG. 1 is a graph showing biomarker levels in suspected lower respiratory infection and/or pneumonia patients versus control subjects.

DETAILED DESCRIPTION

Some embodiments of the current invention are discussed, in detail below. In describing embodiments, specific terminology is employed for the sake of clarity. However, the invention is not intended to be limited to the specific terminology so selected. A person skilled in the relevant art will recognize that other equivalent components can be employed and other methods developed without departing from the broad concepts of the current invention. All references cited anywhere in this specification, including the Background and Detailed Description sections, are incorporated by reference as if each had been individually incorporated.

Some embodiments of the current invention include an innovative method for diagnosing infectious diseases. An example based on an embodiment of the current invention uses the example of pneumonia, with a blood biomarker test based on independently confirmed, genomicaliy-derived markers, In some embodiments, two major innovations are employed: 1) instead of soluble markers, the person's own circulating ceils are used as the ‘canary in the mine’ to sense the pathogen, and 2) solid-phase capture of specific cells, combined with specific fluorochromes used to create a small, sensitive, inexpensive, and rapid assay for infections.

The genomic-scale RNA expression screens of circulating cells described herein reveal, strong cellular markers of pulmonary infections. In some embodiments, the RNA biomarkers are detectable in a handheld nanophotonic assay of whole cells, and are also expressed as changes in the proteins they encode (e.g. amount or activity). The biomarkers described herein can be employed in any of a variety of conventional assays. Although embodiments described herein, are directed to the detection of pneumonia, the markers and assays can also be used to diagnose other types of infections, sand can be readily adapted, for other specific applications, such as appendicitis (e.g. caused by an infection), CNS infections, parasitic infections, and any situation where the immune system detects a pathogen.

Some embodiments of the present invention include methods and kits for assessing and treating lower respiratory infections in a subject, and more particularly to assessing and treating lower respiratory infections in a subject using the analysis of biomarkers isolated from the subject,

In some embodiments, the invention relates to a method of diagnosing a lower respiratory infection in a subject, including the steps: obtaining a biological sample from the subject; detecting expression levels of one or more biomarkers in the biological sample selected from the group consisting of Neutrophil defensin 1 precursor, Defensin alpha 1, LOC653600, defensin alpha 1B, Src homology 2 domain containing transforming protein 3, myeloperoxidase, lipocalin 2, cathepsin G, bactericidal/permeabiHty-increasing protein, iactotransferrin (LTF), solute carrier family 22 member 2, methyltransferase like 7B, resistin, zinc finger protein 90, family with sequence similarity 46 member C, solute carrier family 7 member 5, aminolevulinate delta-synthase 2, 5′-nucleotidase domain containing 2, LOC646021, G antigen 12F, LOC100 133075, hypothetical protein FLJ23865, RST17329 Athersys RAGE Library cDNA, hypothetical protein LOC339047 transcript variant 74, CD40 molecule TNF receptor superfamily member 5 transcript variant 2, splicing factor 1 transcript variant 4, synaptophysm-like 1 transcript variant 1, selenoprotein P plasma 1 transcript variant 1, cDNA DKFZp779F0411, LOC643037, SH3-domain GRB2-like (endopliilin) interacting protein 1, microRNA 940, PR domain containing 12, IMAGE clone 15667343, LOC100128771, LOC732387, region containing hypothetical protein LOC283970 transcript va{dot over (r)} ant 2 LOC643943, hypothetical protein LOC100 129705, LOC728522, regulator of G-protein signaling 20 transcript variant 1, kelch domain containing 1, LOC100 134669, tripartite motif-containing 34 transcript variant 2, ribosomal protein LlO-like, LOCI 00129929. LOC4Q2377, LOC642073, zinc linger protein 461, creatine kinase mitochondrial IB, yy43f04.s1 Soares melanocyte 2NbHM cDNA clone, KIAA1045, ZNF788, primary neuroblastoma clone:Nblal0527, processing of precursor 5 ribonuclease P/MRP subunit transcript variant 2, myelin transcription factor 1-like, neuroblastoma breakpoint family member 7, phosphoiipase C-like 1, LOC391761, LOC646498, solute carrier family 7 member 6 transcript variant. 2, LOC1001 34648, neuroblastoma breakpoint family member 1 transcript variant 16, absent in melanoma Hike, RPS8-like 2, angiopoietin-like 6, LOC645743, V-set and transmembrane domain containing 2A, chemokine binding protein 2. LOC647121, family with sequence similarity 19 (chemokine (C-C motif)-like) member A2, gamma-glutamyltransferase light chain 1 transcript variant A, LOC439949, LOC653157, neurotrophin 3, LOC649686, zinc finger protein 830 (ZNF830), glycerol kinase 5, leucine-rich repeat-containing G protein receptor 6 transcript variant 3, small nucleolar RNA C/D box 13, cDNA FIJ 1 1554 fis clone HEMBA1003037, zinc finger protein 485; and determining the expression levels of the one or more biomarkers by comparing the expression levels of the one or more biomarkers to at least one invariant control marker wherein an increase or decrease in the level of expression of the one or more biomarkers as compared to the at least one invariant control marker is indicative of a lower respiratory infection.

In some embodiments, the invention relates to a method of diagnosing a lower respiratory infection in a subject, including the steps: obtaining a biological sample from the subject; detecting expression levels of at least three biomarkers in the biological sample selected from the group consisting of Neutrophil defensin 1 precursor, Defensin alpha 1, LOC653600, defensin alpha 1B, Sre homology 2 domain containing transforming protein 3, myeloperoxidase, lipocalin 2, cathepsin G, bactencidal/permeability-increasing protein, lactotransferrin (LTF), solute carrier family 22 member 2, methyltransferase like 7B, resistin, zinc finger protein 90, family with sequence similarity 46 member C, solute carrier family 7 member 5, aminolevulinate delta-synthase 2, 5′-nucleotidase domain containing 2, LOC646021, G antigen 12F, LOC100133075, hypothetical protein FLJ2386S, RST17329 Athersys RAGE Library cDNA, hypothetical protein LOC339047 transcript variant 74, CD40 molecule TNF receptor superfamily member 5 transcript variant 2, splicing factor 1 transcript variant 4, synaptophysin-like 1 transcript variant 1, selenoprotein P plasma 1 transcript variant 1, cDNA DKFZp779F0411, LOC643037, SH3-domain GRB2-like (endophilin) interacting protein 1, microRNA 940, PR domain containing 12, IMAGE clone 15667343, LOC10012877L LOC732387, region containing hypothetical, protein LOC283970 transcript variant 2 LOC643943, hypothetical protein LOC100129705, LOC728522, regulator of G-protein signaling 20 transcript variant 1, ketch domain containing 1, LOCI 00134669, tripartite motif-containing 34 transcript variant 2, ribosomal protein LlO-like, LOG 100129929, LOC402377, LOC642073, zinc finger protein 461, creatine kinase mitochondrial 1B, yy43f04.s1 Soares melanocyte 2NbHM cDNA clone, KIAA1045, ZNF788, primary neuroblastoma clone:Nblal0527, processing of precursor 5 ribonuclease P/MRP subiinit transcript variant 2, myelin transcription factor 1-like, neuroblastoma breakpoint family member 7, phospholipase C-like 1, LOC391761, LOC646498, solute carrier family 7 member 6 transcript variant 2, LOC100134648, neuroblastoma breakpoint family member 1 transcript variant 16, absent in melanoma 1-like, EPS8-like 2, angiopoietin-like 6, LOC645743, V-set and transmembrane domain containing 2A, chemokine binding protein 2, LOC647121, family with, sequence similarity 19 (chemokine (C-C motif)-like) member A2, gamma-glutamyltransferase light chain 1 transcript variant A, LOC439949, LOC653157, neurotrophin 3, LOC649686, zinc finger protein 830 (ZNF830), glycerol kinase 5, leucine-rich repeat-containing G protein receptor 6 transcript variant 3, small nucleolar RNA C/D box 13, cDNA FLJ1 1554 fits clone HEMBA1 003037, zinc finger protein 485; and determining the expression levels of the at least three biomarkers by comparing the expression levels of the at, least three biomarkers to at least one inva{dot over (r)}iant control marker wherein an increase or decrease in the level of expression of the at least three biomarkers as compared to the at least one invariant control marker is indicative of a lower respiratory infection,

Some embodiments of the present invention relate to a method of diagnosing a lower respiratory infection in a subject comprising calculating a biomarker infection score from an increase or decrease in the expression levels of one or more biomarkers and comparing said biomarker infection score to a control score.

Some embodiments of the present invention relate to a method of diagnosing a lower respiratory infection in a subject comprising determining the expression levels of one or more biomarkers and at least one invariant control marker by using a multivariate prediction model to determine if a pattern of expression of said one or more biomarkers is indicative of a lower respiratory infection.

Some embodiments of the present invention relate to a method of diagnosing a lower respiratory infection in a subject, wherein a blood sample is used as a biological sample,

Some embodiments of the present invention relate to a method of diagnosing a lower respiratory infection in a subject comprising isolating immune cells from a blood sample,

Some embodiments of the present invention relate to a method of diagnosing a lower respiratory infection in a subject comprising isolating neutrophils, T-cells, or a combination thereof from the subject,

Some embodiments of the present invention relate to a method of diagnosing a lower respiratory infection in a subject comprising detecting expression levels of one or more biomarkers by measuring RNA levels of the one or more biomarkers,

Some embodiments of the present invention relate to a method of diagnosing a lower respiratory infection in a subject comprising measuring RNA levels of one or more biomarkers by using fluorescently-labeled probes complementary to the one or more biomarkers, a ligase-based assay, reverse transcriptase and polymerase chain reaction, RNA sequencing, or cDNA microarray.

Some embodiments of the present invention relate to a method of diagnosing a lower respiratory infection in a subject comprising detecting expression levels of one or more biomarkers selected from the group consisting of bactericidal/permeability-increasing protein, myeloperoxidase, resistin, G antigen 12F, CD40 molecule TNF receptor superfamily member 5 transcript variant 2 and splicing factor 1 transcript variant 4.

Some embodiments of the present invention relate to a method of diagnosing a lower respiratory infection in a subject comprising detecting expression levels of one or more biomarkers selected from the group consisting of alkaline phosphatase liver isotbrm (ALPL), interleukin-S receptor-beta (IL8RB), and Defensin alpha 1.

Some embodiments of the present invention relate to a method of diagnosing a lower respiratory infection hi a subject comprising detecting expression levels of one or more biomarkers and at least one invariant control marker selected from the group consisting of Spi-B transcription factor, protein phosphatase 1 regulatory subunit 21 (PPP 1R21, KLRAQ1), mitogen-activated protein kinase kinase, kinase 7 (MAP3K7, TAK1), olfactory receptor family 51 subfamily member 1 (OR51M 1), BCL2 antagonist/killer (BAK 1), and adenosine deaminase, RNA-specific (ADAR1).

Some embodiments of the present invention include a method of treating a lower respiratory infection in a subject, including the steps of: obtaining a biological sample from the subject; detecting expression levels of one or more biomarkers in the biological sample selected from the group consisting of Neutrophil defensin 1 precursor, Defensin alpha 1, LOC653600, defensin alpha IB, Src homology 2 domain containing transforming protein 3, myeloperoxidase, lipocalin 2. cathepsin G, bactericidal/permeability-increasing protein, lactotransferrin (LTF), solute carrier family 22 member 2, methyl transferase like 7B, resistin, zinc finger protein 90, family with sequence similarity 46 member C, solute carrier family 7 member 5, aminoleviilmate delta-synmase 2, 5′-nucleotidase domain containing 2, LOC646021, G antigen 12F, LOC100133075, hypothetical protein FLJ23865, RST17329 Athersys RAGE Library cDNA, hypothetical protein LOC339047 transcript variant 74, CD40 molecule TNF receptor superfamily member 5 transcript variant 2, splicing factor 1 transcript variant 4, synaptophysin-like 1 transcript variant 1, selenoprotein P plasma 1 transcript variant 1, cDNA DKFZp779F0411, LOC643037, SH3-domain GRB2-like (endophilin) interacting protein 1, microRNA 940, PR domain containing 12, IMAGE clone 15667343, LOC100128771, LOC732387, region containing hypothetical protein LOC283970 transcript variant 2 LOC643943, hypothetical protein LOCI 00129705, LOC728522, regulator of G-protein signaling 20 transcript variant 1, kelch domain containing 1, LOG100134669, tripartite motif-containing 34 transcript variant 2, ribosomal protein LlO-like, LOC100129929, LOC402377, LOC642073, zinc finger protein 461, creatine kinase mitochondrial IB, yy43fl)4.s1 Soares melanocyte 2NbHM cDNA clone, KIAA1045, ZNF788, primary neuroblastoma clone:Nblal0527, processing of precursor 5 ribonuclease P/MRP subunit transcript variant 2, myelin transcription factor 1-like, neuroblastoma breakpoint family member 7, phospholipase C-like 1, LOC391761, LOC646498, solute carrier family 7 member 6 transcript variant 2, LOCI 00134648. neuroblastoma breakpoint family member 1 transcript variant 16, absent in melanoma 1-like, EP88-like 2, angiopoietin-like 6, LOC645743, V-set and transmembrane domain containing 2A, chemokine binding protein 2, LOC647121, family with sequence similarity 19 (chemokine (C-C motif)-like) member A2, gamma-glutamyltransferase light chain 1 transcript variant A, LOC439949, LOC653157, neurotrophin 3, LOC649686, zinc finger protein 830 (ZNF830), glycerol kinase 5, leucine-rich repeat-containing G protein receptor 6 transcript variant 3, small nucleolar RNA C/D box 13, cDNA FIJI 1554 fis clone HEMBA1003037, zinc finger protein 485; determining an increase or decrease in the expression levels of said one or more biomarkers by comparing the expression levels of said one or more biomarkers to at least one invariant control marker wherein an increase or decrease in the level of expression of said one or more biomarkers as compared to the at least one invariant control marker is indicative of a lower respiratory infection; and treating the subject for a lower respiratory infection.

Some embodiments of the present invention include a method of treating, a lower respiratory infection in a subject, including the steps of: obtaining a biological sample from the subject; detecting expression levels of at least three biomarkers in the biological sample selected from the group consisting of Neutrophil defensin 1 precursor, Defensin alpha 1, LOC653600, defensin alpha IB, Src homology 2 domain containing transforming protein 3, myeloperoxidase, lipocalin 2, cathepsin G, bactericidal/permeability-increasing protein, lactotransfer{dot over (r)} n (CIF), solute carrier family 22 member 2, methyltransferase like 7B, resisting zinc finger protein 90, family with sequence similarity 46 member C, solute carrier family 7 member 5, aminolevulmate delta-synthase 2, 5′-nucieotidase domain containing 2, LOC646021, G antigen 12F, LOCI 00133075, hypothetical protein FLJ23865, RST17329 Athersys RAGE library cDNA, hypothetical protein LOC339047 transcript variant 74, CD40 molecule TNF receptor superfamily member 5 transcript variant 2, splicing factor 1 transcript variant 4, synaptophysin-like 1 transcript variant 1, selenoprotein P plasma 1 transcript variant 1, cDNA DKFZp779F041 1, LOC643037, SH3-domain GRB2-like (endophilm) interacting protein 1, rnieroRNA 940, PR domain containing 12, IMAGE clone 15667343, LOC100128771, LOC732387, region containing hypothetical protein LOC283970 transcript variant 2 LOC643943, hypothetical protein LOCI 00129705, LOC728522, regulator of G-protein signaling 20 transcript variant 1, kelch domain containing 1. LOC100134669, tripartite motif-containing 34 transcript variant 2, ribosomal protein LI0-like, LOCI 00129929, LOC402377, LOC642073, zinc finger protein 461, creatine kinase mitochondrial IB, yy43f04.s1 Soares melanocyte 2NbHM cDNA clone, KIAA1045, ZNF788, primary neuroblastoma done:Nblal0527, processing of precursor 5 ribonuclease P/MRP subunit transcript variant 2, myelin transcription factor 1-like, neuroblastoma breakpoint family member 7, phospholipase 1, LOC391761, LOC646498, solute earner family 7 member 6 transcript variant 2, LOC100 134648, neuroblastoma breakpoint family member 1 transcript variant 16, absent in melanoma 1-like, EPS8-like 2, angiopoietin-like 6, LOC645743, V-set and transmembrane domain containing 2A, chernokine binding protein 2, LOC647121, family with sequence similarity 19 {chernokine (C-C motif)-like) member A2, gamma-glutamyltransterase light chain 1 transcript variant A, LOC439949, LOC653157, neurotrophin 3, LOC649686, zinc finger protein 830 (ZNF830), glycerol kinase 5, ieucme-rich repeat-containing G protein receptor 6 transcript variant 3, small nucleolar RNA C/D box 13, cDNA FIJI 1554 fis clone HEMBA1003037, zinc finger protein 485; determining an increase or decrease in the expression levels of said at least three biomarkers by comparing the expression levels of said at least three biomarkers to at least one invariant control marker wherein an increase or decrease in the level of expression of said at least three biomarkers as compared to the at least one invariant control marker is indicative of a lower respiratory infection; and treating the subject for a lower respiratory infection,

Some embodiments of the present invention relate to a method of treating a lower respiratory infection in a subject, wherein treating the subject for a lower respiratory infection comprises administering antibiotics to said subject, administering antivirals to said subject, administering anti-inflammatories to said subject, or a combination thereof.

Some embodiments of the present invention relate to a method of treating a lower respiratory infection in a subject by calculating a biomarker infection score from said increase or decrease in the expression levels of said one or more biomarkers and comparing said biomarker infection score to a control score.

Some embodiments of the present invention relate to a method of treating a lower respiratory infection in a subject by determining an increase or decrease in the expression levels of one or more biomarkers comprising using a multivariate prediction model to determine if a pattern of expression of said one or more biomarkers is indicative of a lower respiratory infection.

Some embodiments of the present invention relate to a method of treating a lower respiratory infection in a subject by obtaining a blood sample from the subject and determining an increase or decrease in the expression levels of one or more biomarkers.

Some embodiments of the present invention relate to a method of treating a lower respiratory infection in a subject including isolating immune cells from a blood sample from the subject.

Some embodiments of the present invention relate to, a method of treating, a lower respiratory infection in a subject comprising isolating neutrophils, T-cells, or a combination thereof from the subject.

Some embodiments of the present invention relate to a method of treating a lower respiratory infection in a subject comprising detecting expression levels of one or more biomarkers by measuring RNA levels of said one or more biomarkers.

Some embodiments of the present invention relate to a method of treating a lower respiratory infection in a subject comprising measuring RNA levels of one or more biomarkers by using fluorescently-labeled probes complementary to the said biomarkers, a ligase-based assay, reverse transcriptase and polymerase chain reaction, RNA sequencing or cDNA raicroarray.

Some embodiments of the present invention relate to a method of treating a lower respiratory infection in a subject comprising determining expression levels of one or more biomarkers selected from the group consisting of bactericidal/permeability-increasing protein, myeloperoxidase, resistin, G antigen 12F, CD40 molecule TNF receptor superfamily member 5 transcript variant 2, and splicing factor 1 transcript variant 4.

Some embodiments of the present invention relate to a method of treating a lower respiratory infection in a subject comprising determining expression levels of one or more biomarkers selected from the group consisting of defensin alpha-1, alkaline phosphatase liver isoform (ALPL), interleukin-8 receptor beta (IL8RB).

Some embodiments of the present invention relate to a method to treating a lower respiratory infection in a subject comprising determining expression levels of one or more biomarkers by comparing the expression levels of the one or more biomarkers to at least one invariant control marker selected from the group consisting of Spi-B transcription factor, protein phosphatase 1 regulatory subunit 21 (PPP1R21, KLRAQ1), mitogen-activated protein kinase kinase kinase 7 (MAP3K7, TAK1), olfactory receptor family 51 subfamily member 1 (OR51M1), BCL2 antagonist/killer (BAK1), and adenosine deaminase, RNA-specific (ADAR1).

Some embodiments of the present invention include a kit for use in diagnosing lower respiratory infection in a subject comprising; agents that specifically bind one or more biomarkers selected from the group consisting of Neutrophil defensin 1 precursor, Defensin alpha 1, LOC653600, defensin alpha IB, Src homology 2 domain containing transforming protein 3, myeloperoxidase, lipocalin 2, cathepsin G, bactericidal/permeability-increasing protein, lactotransferrin (LTF), solute carrier family 22 member 2, methyltransferase like 7B, resistin, zinc finger protein 90, family with sequence similarity 46 member C, solute carrier family 7 member 5, amino, evulmate delta-synmase 2, 5′-nucleotidase domain containing 2, LOC646021, G antigen 12F, LOCI 001 33075, hypothetical protein FLJ23865, RST17329 Athersys RAGE Library cDNA, hypothetical protein LOC339047 transcript variant 74, CD40 molecule TNF receptor superfamily member 5 transcript variant 2, splicing factor 1 transcript variant 4, synaptophysin-like 1 transcript variant 1, selenoprotein P plasma 1 transcript variant 1, cDNA DKFZp779F0411, LOC643037, SH3-domain GRB2-like (endophilin) interacting protein 1, microRNA 940, PR domain containing 12 IMAGE clone 15667343, LOC100128771, LOC732387, region containing hypothetical protein LOC283970 transcript variant 2 LOC643943, hypothetical protein LOC100129705, LOC728522, regulator of G-protein signaling 20 transcript variant 1, kelch domain containing 1, LOC100134669, tripartite motif-containing 34 transcript variant 2, ribosomal protein LlO-like, LOC100129929, LOC402377, LOC642073, zinc finger protein 461, creatine kinase mitochondrial IB, w43f04.s1 Soares melanocyte 2NbHM cDNA clone, KIAA1Q45, ZNF788, primary neuroblastoma clone:Nblai0527, processing of precursor 5 ribonuclease P/MRP subunit transcript variant 2, myelin transcription factor 1-like, neuroblastoma breakpoint family member 7, phospholipase C-like 1, LOC391761; LOC646498, solute carrier family 7 member 6 transcript variant 2, LOG1001 34648, neuroblastoma breakpoint family member 1 transcript variant 16, absent in melanoma 1-like, EPS8-like 2, angiopoietin-like 6, LOC645743, V-set and transmembrane domain containing 2A, chemokine binding protein 2, LOC647121, family with sequence similarity 19 (chemokine (C-C motif)-like) member A2, gamma-glutamyltransferase light chain 1 transcript variant A, LOC439949, LOC653157, neurotrophin 3, LOC649686, zinc finger protein 830 (ZNF830), glycerol kinase leucine-ricb repeat-containing G protein receptor 6 transcript variant 3, small nucleolar RNA C/D box 13, cDNA FIJI 1554 fis clone HEMBA1003037, zinc finger protein 485: agents that specifically bind to at least one invariant control marker; a container for housing said agents; and instructions for use of the agents for determining an increase or decrease in the expression levels of said one or more biomarkers by comparing the expression levels of said one or more biomarkers to said at least one invariant control marker wherein an increase or decrease in the level of expression of said one or more biomarkers as compared to the at least one invariant control marker is indicative of a lower respiratory infection.

Some embodiments of the present invention include a kit for use in diagnosing a lower respiratory infection in a subject comprising: agents that specifically bind at least three biomarkers selected from the group consisting of Neutrophil defensin 1 precursor, Defensin alpha 1, LOC6S3600, defensin alpha IB, Src homology 2 domain containing transforming protein 3, myeloperoxidase, lipocalin 2, cathepsin G bactericidal/permeability-increasing protein, lactotransferrin (LTF), solute carrier family 22 member 2, methyltransferase like 7B, resistin, zinc finger protein 90, family with sequence similarity 46 member C, solute carrier family 7 member 5, aminolevulinate delta-synthase 2, 5′-nucleotidase domain containing 2, LOC646021, G antigen 12F, LOC100133075, hypothetical protein FLJ23865, RST17329 Athersys RAGE Library cDNA, hypothetical protein LOC339047 transcript variant 74, CD40 molecule TNF receptor superfamily member 5 transcript variant 2, splicing factor 1 transcript variant 4, synaptophysin-like 1 transcript variant 1, selenoprotein P plasma 1 transcript variant 1, cDNA DKFZp779F0411, LOC643037, SH3-domain GRB2-Sike (endophilin) interacting protein 1, microRNA 940, PR domain containing 12, IMAGE clone 15667343, LOC100128771, LOC732387, region containing hypothetical protein LOC283970 transcript variant 2 LOC643943, hypothetical protein LOC100129705, LOC728522, regulator of G-protein signaling 20 transcript variant 1, kelch domain containing 1, LOG 100 134669, tripartite motif-containing 34 transcript variant 2, ribosomal protein LlO-like, LOCI 00129929, LOC402377, LOC642073, zinc finger protein 461, creatine kinase mitochondrial IB, yy43f04.$1 Soares melanocyte 2NbHM cDNA clone, KIAA1045, ZNF788, primary neuroblastoma clone:Nbla 10527, processing of precursor 5 ribonuclease P/MRP subunit transcript variant. 2, myelin transcription factor 1-like, neuroblastoma breakpoint family member 7, phospholipase like 1, LOC391761, LOC646498, solute carrier family 7 member 6 transcript variant 2, LOCI 00134648, neuroblastoma breakpoint family member 1 transcript variant 16, absent in melanoma 1-like, EPS8-Kke 2, angiopoietin-like 6, LOC645743, V-set and transmembrane domain containing 2A, chemokine binding protein 2, LGC647121, family with sequence similarity 19 (chemokine (C-C motif)-like) member A2, gamma-glutamyltransferase light, chain 1 transcript variant A, LOC439949, LOC653157, neurotropism 3, LOC649686, zinc finger protein 830 (ZNF830), glycerol kinase 5, leucine-rich repeat-containing G protein receptor 6 transcript variant 3, small nucleolar RNA C/D box 13, cDNA FLJ11554 fis clone HEMBA1003037, zinc finger protein 485; agents that specifically bind to at least one invariant control marker; a container for housing said agents; and instructions for use of the agents for determining an increase or decrease in the expression levels of said at least, three biomarkers by comparing the expression levels of said at least three biomarkers to said at least one invariant control marker wherein an increase or decrease in the level of expression of said at least three biomarkers as compared to the at least one invariant control marker is indicative of a lower respiratory infection.

Some embodiments of the present invention relate to a kit for use in diagnosing a lower respiratory infection in a subject comprising polynucleotides that specifically bind to RNA transcripts of one or more biomarkers and of at least one invariant control marker.

Some embodiments of the present invention relate to a kit for use in diagnosing a lower respiratory infection in a subject comprising polynucleotides labeled with a detectable marker.

Some embodiments of the present invention relate to a kit for use in diagnosing a lower respiratory infection in a subject comprising polynucleotides that amplify polynucleotides encoding, one or more biomarkers and at least one invariant control marker,

Some embodiments of the present invention relate to a kit for use in diagnosing a lower respiratory infection in a subject comprising instructions for calculating a biomarker infection score from an increase or decrease in the expression levels of one or more biomarkers and comparing said biomarker infection score to a control score.

Some embodiments of the present invention relate to a kit for use in diagnosing a lower respiratory infection in a subject comprising instructions for determining an increase or decrease in the expression levels of one or more biomarkers by using a multivariate prediction model to determine if a pattern of expression of said one or more biomarkers is indicative of a lower respiratory infection,

Some embodiments of the present invention relate to a kit for use in diagnosing lower respiratory infection in a subject comprising agents that specifically bind to one or more biomarkers selected from the group consisting of bactericidal/permeability-increasing protein, myeloperoxidase, resistin, G antigen 12F, CD40 molecule TNF receptor superfamily member 5 transcript variant 2, and splicing factor 1 transcript variant 4,

Some embodiments of the present invention relate to a kit for use in diagnosing a lower respiratory infection in a subject comprising agents that specifically bind to defense alpha-i, alkaline phosphatase liver isoform (ALPL), interleukin-8 receptor beta (IL8RB).

Some embodiments of the present invention relate to a kit for use in diagnosing a lower respiratory infection in a subject comprising agents that specifically bind to at least one invariant control marker selected from the group consisting of actin-beta (ACTB), Spi-B transcription factor, protein phosphatase 1 regulatory subunit 21 (PPP1R21, KLRAQ1), mitogen-activated protein kinase kinase kinase 7 (MAP3K7, TAK1), olfactory receptor family 51 subfamily member 1 (OR51M1), BCL2 antagonist/killer (BAK1), and adenosine deaminase, RN A-specific (ADAR1).

Some embodiments of the present invention relate to a kit for use in diagnosing a lower respiratory infection in a subject comprising reagents for fluorescently-labeled probes complementary to the one or more biomarkers, a ligase-based assay, reverse transcriptase and polymerase chain reaction, RNA sequencing or cDNA microarray.

Some embodiments of the present invention include a method of diagnosing a lower respiratory infection in a subject comprising: obtaining a biological sample from said subject; and contacting the biological sample from said subject with a kit for use in diagnosing a lower respiratory infection in a subject,

Some embodiments of the present invention include a method of treating a lower respiratory infection in a subject comprising: obtaining a biological sample from said subject; contacting the biological sample from said subject with a kit for use in diagnosing a lower respiratory infection in a subject; and treating the subject for a lower respiratory infection by administering antibiotics to said subject, administering antivirals to said subject, administering anti¬inflammatories to said subject, or a combination thereof.

Definitions

To facilitate an understanding of the present invention, a number of terms and phrases are defined below,

As used herein, the singular forms “a”, “an”, and “the” include plural forms unless the context clearly dictates otherwise. Thus, for example, reference to “a binding agent” includes reference to more than one binding agent.

The terms “diagnostic” and “diagnosis” refer to identifying the presence or nature of a pathologic condition and includes identifying patients who are at risk of developing a specific disease or disorder. Diagnostic methods differ in their sensitivity and specificity. The “sensitivity” of a diagnostic assay is the percentage of diseased individuals who test positive (percent of “true positives”). Diseased individuals not detected by the assay are “false negatives.” Subjects who are not diseased and who test negative in the assay, are termed “true negatives.” The “specificity” of a diagnostic assay is 1 minus the false positive rate, where the “false positive” rate is defined as the proportion of those without the disease who test positive. While a particular diagnostic method may not provide a definitive diagnosis of a condition, it suffices if the method provides a positive indication that aids in diagnosis.

The terms “detection”, “detecting” and the like, may be used in the context of detecting bio markers, or of detecting a disease or disorder (e.g., when positive assay results are obtained). In the latter context, “detecting” and “diagnosing” are considered synonymous.

The terms “subject”, “patient” or “individual” generally refer to a human, although the methods of the invention are not limited 0 humans, and should be useful in other mammals (e.g., eats, dogs, etc).

“Sample” is used herein in its broadest sense. A sample may comprise a bodily fluid including blood, serum, plasma, tears, sputum, broncheolar lavage, aqueous and vitreous humor, spinal fluid, urine, and saliva; a soluble fraction of a cell or tissue preparation, or media in which cells were grown. Means of obtaining suitable biological samples are known to those of skill in the art.

An “antibody” is an immunoglobulin molecule that recognizes and specifically binds to a target, such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, etc., through at least one antigen recognition site within the variable region of the immunoglobulin molecule. As used herein, the term is used in the broadest sense and encompasses intact polyclonal antibodies, intact monoclonal antibodies, antibody fragments (such, as Fab, Fab′, F(ab′)2, and Fv fragments), single chain Fv (scFv) mutants, multispecific antibodies such as bispecific antibodies generated from at least two intact antibodies, hybrid, antibodies, fusion proteins comprising an antibody portion, and any other modified immunoglobulin molecule comprising an antigen recognition site so long as the antibodies exhibit the desired biological activity. An antibody may be of any the five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, or subclasses (isotypes) thereof (e.g. IgG1, IgG2, IgG3, igG4, IgA1 and IgA2), based on the identity of their heavy-chain constant domains referred to as alpha, delta, epsilon, gamma, and mu, respectively. The different classes of immunoglobulins have different and well known subunit. structures and three-dimensional configurations. Antibodies may be naked or conjugated to other molecules such as toxins, radioisotopes, enzymes, fluorochromes. etc.

The term “antibody fragments” refers to a portion of an intact antibody. Examples of antibody fragments include, but are not limited to, linear antibodies; single-chain antibody molecules; Fc or Fc′ peptides, Fab and Fab fragments, and multispecific antibodies formed from antibody fragments.

“Hybrid antibodies” are immunoglobulin molecules in which pairs of heavy and light chains from antibodies with different antigenic determinant regions are assembled together so that two different epitopes or two different antigens may be recognized and bound by the resulting tetramer.

“isolated” in regard to cells, refers to a cell that is removed from its natural environment and that is isolated or separated, and is at least about 30%, 50%, 75%, and 90% free from other cells with which it is naturally present, but which lack the marker based on which the cells were isolated.

For use in the diagnostic and therapeutic applications described herein, kits are also within the scope of some embodiments of the current invention. Such kits can comprise a carrier, package or container that is compartmentalized to receive one or more containers such as vials, tubes, and the like, each of the containers) comprising one of the separate elements to be used in the method. For example, the containers) can comprise a probe that is or can be detectably labeled. The probe can be an antibody or polynucleotide specific for a biomarker of interest. Alternatively, the kit can comprise a mass spectrometry (MS) probe. The kit can also include containers containing nucleotide(s) for amplification or silencing of a target nucleic acid sequence, and/or a container comprising a reporter, such as a biotin-binding protein, e.g., avidin or streptavidin, bound to a detectable label, e.g., an enzymatic, florescent, or radioisotope label. The kit can include Fall or part of the amino acid sequence of the biomarker, or a nucleic acid molecule that encodes such amino acid sequences.

A kit according to an embodiment of the current invention may comprise the container described above and one or more other containers comprising materials desirable from a commercial and user standpoint, including buffers, diluents, filters, needles, syringes, and package inserts with instructions for use. In addition, a label can be provided on the container to indicate that the composition is used for a specific therapeutic or non-therapeutic application, and can also indicate directions for either in vivo or in vitro use, such as those described above. Directions and or other information can also be included on an insert that is included with the kit.

Polynucleotides may be prepared using any of a variety of techniques known in the art. The polynucleotide sequences selected as probes (and bind to the biomarkers of interest) should be sufficiently long and sufficiently unambiguous that false positives are minimized. The polynucleotide is preferably labeled such that it can be detected upon hybridization to DNA and/or RNA in the assay being screened. Methods of labeling are well known in the art, and include the use of radiolabels, such as 32P-labeled ATP, biotmylation, fluorescent groups or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are well known in the art,

Polynucleotide variants may generally be prepared by any method known in the art, including chemical synthesis by, for example, solid phase phosphoramidite chemical synthesis, Modifications in, a polynucleotide sequence may also be introduced using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis. Alternatively, DNA and RNA molecules may be generated in vitro or in vivo. Certain portions may be used to prepare an encoded polypeptide,

Any polynucleotide may be further modified to increase stability in vivo and/or in vitro for improved activity and/or storage. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5′ and/or 3′ ends; the use of phosphorothioate or 2′ O-methyl rather than phosphodiesterase linkages in the backbone; and/or the inclusion of nonuraditional bases such as inosine, queosine and wybutosine, as well as acetyl- methyl-, thio- and other modified forms of adenine, cytidine, guanine, thymine and uridine.

Polynucleotides and/or antibodies specific to biomarkers of interest can be conjugated to detectable markers to a second molecule. Suitable detectable markers include, but are not limited to, a radioisotope, a fluorescent compound, a biolummescent compound, chemiluminescent compound, a metal chelator or, an enzyme. A second molecule for conjugation can be selected in accordance with the intended use. For example, for therapeutic use, the second molecule can be a toxin or therapeutic agent. Further, bi-specific antibodies specific for two or more biomarkers may be generated using methods generally known in the art. Homodimeric antibodies may also be generated by cross-linking techniques known in the art.

EXAMPLES

The following examples help explain some concepts of the current invention. However, the general concepts of the current invention are not limited to the particular examples.

Example 1: Blood Biomarkers for Respiratory Infections

The following factors are taken into consideration in this embodiment of the present invention:

1) Sample: In some embodiments, whole blood is the primary type of sample, in which the whole blood is drawn into a suitable preservative known to stabilize and protect the RNA. Blood drawn by venipuncture, in-dwelling catheter, or finger stick, are recognized and reliable methods of obtaining a blood sample from a human or other subject.

2) Time/Cost. Time is a major design driver. Prolonged analytical time a) delays treatment, b) requires revisit by the sick patient, and c) increases exposures to family and other patients. The use of RNA and/or cell-based systems could dramatically reduce time sand costs because the volume of reagents in a microchamber can be extremely efficient and the time of quantitation can be reduced to hours or minutes, depending on the technology employed,

3) Sensitivity. In many infections, including LRI, and especially appendicitis (e.g. resulting from infection), sinus infections, and brain infections, the pathogen may never circulate at detectable levels in blood. In many cases, bacteria can form ‘biofilms’, which can line the appendix, lungs, or sinuses and cause extreme inflammation without ever circulating in blood. However, the presently claimed method takes advantage of the fact that the blood will contain immune cells that have passed close, enough b become activated by pathogen-derived diffusible signals, such as endotoxin and butyrate.

4) Selectivity, A cell-based system can distinguish viral from bacterial infections because the cellular-systems that respond to viruses and bacteria are quite different. Viral markers as well as bacterial markers can be used in embodiments of the invention. Clearly, the first question is really whether the person has an infection, versus an inflammatory reaction to allergens, a persistent inflammatory condition, such as bronchitis, asthma, or chronic obstructive pulmonary disease (COPD), which are treated very differently from an infection. By ruling out an infection, the doctor can decide, whether antihistamines for allergy, or steroids for bronchitis are more appropriate.

Identification of Biomarkers in Blood.

Using genomic-scale RNA transcript profiling, 79 RNA markers in blood were identified. Any of these (alone or in combination with other of the biomarkers) constitute a predictive biomarker of infection. These biomarkers are used in any of a variety of conventional test formats, such as measuring RNA level, protein level, or protein activity.

Methods: A total of >270 patients presenting to the GW Emergency Department were consented for a blood sample by venipuncture under an IRB-approved protocol. Their clinical course was unaffected by study procedures. Based on the final diagnosis, subsets of patients were analyzed by advanced genomic-scale RNA expression profiling of their blood using Illumina BeadChip Arrays (v12.4). Expression profiles from patients with acute appendicitis (APP), lower respiratory infection (LRI), or a presumably non-infectious control, abdominal hernia (HER), were compared to identify differentially expressed genes (DEG). The studies herein are focused on the LRI patients (n−5) compared to APP (n=9) and HER (η{circumflex over ( )}M), in which APP and HER are pooled to form a Control group (Con),

Targets: The gene expression profiling reported herein revealed 79 transcripts (16 increased, 63 decreased) that were changed more than 3-fold at an uncorrected p value of <0.001 (Table 1). Furthermore, 11 of these transcripts were elevated more than 6-fold and 51 decreased in LRI by more than 6-fold, providing good signal/noise ratio for a biomarker. Published microarray analysis of whole blood RNA from chronic obstructive pulmonary disease (COPD) patients has identified some of the markers described herein. However, their levels were associated with the primary endpoint of ICU vs non-ICU status of the patient, and not. specifically the presence of a respiratory infection (ALmansa 2012). In embodiments of the present invention, markers that are specifically associated with respiratory infections are employed in order to detect infections in a patient without regard b ICU status, but rather as general guide to a physician in determining therapy. In some embodiments of the present invention, the previously identified markers are used in conjunction with one or more new markers that are identified herein.

Examples of LRI biomarkers in blood: (A full list of the 79 biomarkers is found in ‘fable 1 below)

Transcripts elevated in LRI; Of the 79 transcripts, 16 transcripts were increased in LRI, and several of these transcripts have known proteins, some of which have been associated with the response to infection. However, the levels of these RNAs have not been shown to be diagnostic of infection. Exemplary markers that are used in embodiments of the invention include;

Bactericidaypenneability-increasing protein (BPI), increased >7-fold in LRI, is known to b e elevated in patients with LRI (Lange 2013). Patients with severe sepsis show elevated plasma levels of BPI protein, defensin A1 (DEFA1) protein, and lactoferrin (LTV) protein (Berkested t 2010). In some embodiments of the present invention, the previously identified markers are used in conjunction with one or more new markers that are identified herein.

Myeloperoxidase (MPQ), increased >9-fold in LRI, is a neutrophil granule protein, which works with NADPH oxidase to convert H202 to hypochlorous acid (bleach), which is a potent mierobtocidal agent. MPO generates bleach in high concentrations within the phagosome that engulfs bacteria into the neutrophil. While MPO mRNA is induced in LRI patients, secreted MPO protein in plasma is complicated due to specific neutralization of MPO in plasma by agents such as cerruloplasmin, which limits the utility a simple MPO activity test on plasma. Thus, cellular levels of MPO mRNA or protein are likely useful biomarkers for diagnostic tests.

Resistin (RETN), increased −6-fold in LRI, is stored in neutrophil granules and released upon neutrophil activation, along with lactoferrin and CR3/CDllb (Bostrom 2009). Plasma levels of resistin, N GAL, and IL-8 distinguished uncomplicated sepsis from septic shock (Macdonaki 2014). Resistin protein is elevated in septic patients, and released from neutrophils by streptococcal cell wall (Johansson 2009). Resistin RNA and protein are principally in neutrophils, and to a lesser degree monocytes. Resistin RNA expression is induced by Hpopolysaccharide (LPS) in neutrophils and U937 (Kunnari AM 2009 19445973), However, RE TN has not been previously shown to be a predictive marker of infection (e.g. in humans),

Defensins (DEFA1B, HNP-L LOC653600) are a group of small peptides that are intrinsically involved in the host defense against pathogens. Typically contained within the azurophilic neutrophil granules, these proteins can directly attack bacteria, and potentially viruses, when they internalized within a host immune cell such as the neutrophil. The specific defensins identified in our microarray screen are multiple transcripts which derive from the DEFA1/3 locus in the genome at the location chr8:6,977,650-7,018,500 in the hg38 genome build, A variety of transcripts and proteins are made from this locus which are categorized as DEFA1 or DEFA3 depending on the usage of the included exons. For the purposes of the present invention, any transcripts derived from this locus may be suitable for diagnosis, and the DEFA1 version of the mRNA is used for demonstration of the utility, but is not limiting in practice of the invention,

Transcripts which are decreased in LRI:

GAGE12F transcript is decreased ˜17-fold in patients with LRL No biological or physiological function has been described for GAGE12F, and, it has not been shown previously to be a biomarker for infection,

CD40 transcript is >12-fold decreased in patients with LRL GD40 is a well-known protein that is grouped into the Tumor Necrosis Factor (TNF) receptor superfamily. However, decreased mRNA levels of CD40 have not been shown previously to be correlated with LRI or any other infection,

Splicing factor 1 (SF1) transcript variant 4, is decreased >12-fold in patients with LRI, SF1 is a well-known protein involved in regulating the splicing of certain transcripts in diverse settings. However, decreased mRNA levels of SF1 (e.g. of transcript variant 4) have not been shown previously to be correlated with bacterial or viral infection, e.g. of humans,

Invariant transcripts to be used as controls:

There are numerous transcripts that do not change between groups, and these can be used as ‘normalizing’ genes (controls) to compensate for handling and technical errors that might affect a particular sample. Examples of invariant gene transcripts include KLRAQ1, MAP3K7, OR51M1, BAK1, and ADAR1, although this list is not meant to be exclusive of other invariant transcripts.

Calculation of the Infection Score:

The normalized signal values (SV) of 3 increased transcripts (RSTN, BPi, MPO) are added together and divided by the sum of the 3 invariant SVs, Likewise, the 3 decreased transcripts (GAGE12F, CD40, SF1) are added together and divided by the sum of 3 invariant transcripts. In one embodiment, ÷12.5 fold is added to [−14 fold] to create a score of 26.5, there would thus be a normal range and escalating probabilities of infection.

TABLE 1 Differentially expressed gene transcripts relevant to lower respiratory infection. ProbeID p-value FC (abs) Con LRI DEFINITION 770400 3.61E−04 17.78 UP 0.43 4.58 Neutrophil defensin 1 precursor (HNP- 1) (HP-1) (HP1) (Defensin, alpha 1) (LOC653600), mRNA. 7150170 8.79E−04 15.79 UP 2.62 6.60 defensin, alpha 1B (DEFA1B), mRNA. 6040689 7.25E−04 9.32 UP −5.04 −1.82 SHC (Src homology 2 domain containing) transforming protein 3 (SHC3), mRNA. 3520601 8.41E−05 9.29 UP −0.31 2.91 myeloperoxidase (MPO), nuclear gene encoding mitochondrial protein, mRNA. 4390398 2.40E−04 8.80 UP 3.04 6.18 lipocalin 2 (LCN2), mRNA. 1500735 8.77E−04 7.95 UP 0.08 3.07 cathepsin G (CTSG), mRNA. 4200746 4.41E−04 7.48 UP 0.20 3.11 bactericidal/permeability-increasing protein (BPI), mRNA. 5550367 7.76E−04 6.98 UP 0.58 3.38 lactotransferrin (LTF), mRNA. 2340156 2.69E−04 6.85 UP −6.14 −3.37 solute carrier family 22 (organic cation transporter), member 2 (SLC22A2), mRNA. 5310142 3.33E−04 6.60 UP −1.66 1.06 methyltransferase like 7B (METTL7B), mRNA. 4610129 9.27E−04 6.24 UP 0.86 3.50 resistin (RETN), mRNA. 5360427 6.81E−04 5.52 UP −5.55 −3.08 zinc finger protein 90 (HTF9) (ZNF90), mRNA. 6860347 8.48E−05 3.93 UP 4.82 6.80 family with sequence similarity 46, member C (FAM46C), mRNA. 270152 2.80E−04 3.38 UP 1.57 3.33 solute carrier family 7 (cationic amino acid transporter, y+ system), member 5 (SLC7A5), mRNA. 5270338 8.32E−04 3.19 UP −1.00 0.68 aminolevulinate, delta-, synthase 2 (ALAS2), nuclear gene encoding mitochondrial protein, transcript variant 3, mRNA. 6840301 8.42E−04 3.13 UP −0.40 1.25 5′-nucleotidase domain containing 2 (NT5DC2), mRNA. 4060551 5.30E−07 19.07 Down −2.12 −6.37 PREDICTED: similar to hCG1774990 (LOC646021), mRNA. 6620326 1.00E−04 17.03 Down −2.28 −6.37 G antigen 12F (GAGE12F), mRNA. 990170 1.14E−05 15.29 Down −1.09 −5.03 PREDICTED: misc_RNA (LOC100133075), miscRNA. 4880280 4.09E−05 14.11 Down −2.55 −6.37 PREDICTED: hypothetical protein FLJ23865 (FLJ23865), mRNA. 430162 4.06E−04 13.26 Down −2.64 −6.37 RST17329 Athersys RAGE Library cDNA, mRNA sequence 1240382 1.11E−04 13.03 Down −1.56 −5.26 PREDICTED: hypothetical protein LOC339047, transcript variant 74 (LOC339047), mRNA. 3370138 1.25E−04 12.53 Down −0.82 −4.47 CD40 molecule, TNF receptor superfamily member 5 (CD40), transcript variant 2, mRNA. 3610743 4.35E−04 12.30 Down 0.16 −3.46 splicing factor 1 (SF1), transcript variant 4, mRNA. 5340224 5.34E−05 11.75 Down −2.81 −6.37 synaptophysin-like 1 (SYPL1), transcript variant 1, mRNA. 4280678 3.15E−04 11.25 Down −2.24 −5.73 selenoprotein P, plasma, 1 (SEPP1), transcript variant 1, mRNA. 6350093 3.87E−04 11.08 Down −1.57 −5.04 mRNA; cDNA DKFZp779F0411 (from clone DKFZp779F0411) 5390717 5.01E−05 10.87 Down −1.40 −4.85 PREDICTED: similar to hCG1730248 (LOC643037), mRNA. 6380239 7.33E−04 10.82 Down −2.73 −6.17 SH3-domain GRB2-like (endophilin) interacting protein 1 (SGIP1), mRNA. 5860484 4.55E−05 10.69 Down −1.65 −5.07 microRNA 940 (MIR940), microRNA. 6580619 4.20E−04 10.68 Down −2.95 −6.37 PR domain containing 12 (PRDM12), mRNA. 5810113 8.74E−04 10.59 Down −2.76 −6.17 oo20c08.x1 Soares_NSF_F8_9W_OT_PA_P_S1 cDNA clone IMAGE: 1566734 3, mRNA sequence 4390528 4.16E−04 10.26 −1.83 −5.19 PREDICTED: misc_RNA (LOC100128771), miscRNA. 5890598 3.41E−05 10.19 Down −2.18 −5.53 PREDICTED; similar to ring finger protein 18 (LQC732387), mRNA. 6770068 2.91E−04 9.77 Down −2.88 −6.17 PREDICTED: region containing hypothetical protein LOC283970; similar to nuclear pore complex interacting protein, transcript variant 2 (LOC643943), mRNA. 7570431 1.47E−04 9.50 Down −1.37 −4.62 PREDICTED: hypothetical protein LOC100129705 (LOC100129705), mRNA. 2650128 9.05E−05 9.40 Down −2.47 −5.70 PREDICTED: misc_RNA (LOC728522), miscRNA. 6400403 2.12E−04 9.27 Down −2.36 −5.57 regulator of G-protein signaling 20 (RG820), transcript variant 1, mRNA. 2190100 9.82E−04 9.11 Down −1.83 −5.02 keich domain containing 1 (KLHDC 1), mRNA. 6650192 7.74E−04 9.01 Down −2.02 −5.19 PREDICTED: misc_RNA (LOC100134669), miscRNA, 2450300 6.13E−04 8.98 Down −3.20 −6.37 tripartite motif-containing 34 (TRIM34), transcript variant 2, mRNA. 5050072 3.85E−05 8.96 Down −1.43 −4.59 ribosomal protein LlO-like (RPLIOL), mRNA. 4050482 7.43E−04 8.70 Down −2.47 −5.59 PREDICTED: similar to Fanconi anemia complementation groDOWN D2 protein (LOC100129929), mRNA. 770110 5.48E−04 8.61 Down −2.12 −5.23 PREDICTED: similar to UDP- Gal: betaGicNAc beta 1,3- galactosyltransferase, polypeptide 4 (LOC402377), mRNA. 3060520 7.72E−04 8.60 Down −0.20 −3.30 PREDICTED: similar to MHC class II antigen (LOC642073), mRNA. 1820474 5.80E−04 8.36 Down −2.47 −5.53 zinc finger protein 461 (ZNF461), mRNA. 5570021 4.57E−04 8.31 Down −2.60 −5.65 creatine kinase, mitochondrial 1B (CKMT1 B), nuclear gene encoding mitochondrial protein, mRNA. 1010072 3.14E−04 8.16 Down −1.71 −4.74 yy43ii)4.si Scares melanocyte 2NbHM cDNA clone IMAGE; 274015 3, mRNA sequence 2100162 9.49E−04 8.11 Down −2.06 −5.08 KIAA1045 (KÏAA 1045), mRNA. 5810682 1.58E−04 8.09 Down −1.87 −4.89 PREDICTED: misc_RNA (ZNF788), miscRNA, 6370228 6.94E−05 8.04 Down 0.09 −2.92 primary neuroblastoma cDNA, clone: Nbla10527, full insert sequence 6550484 3.42E−04 8.03 Down −1.97 −4.97 processing of precursor 5, ribonuclease P/MRP subunit (S. cerevisiae) (POPS), transcript variant 2, mRNA. 2190358 2.25E−04 7.86 Down −1.94 −4.92 myelin transcription factor 1-like (MYTI L), mRNA. 4590037 1.10E−04 7.81 Down −1.39 −4.36 neuroblastoma breakpoint family, member 7 (NBPF7), mRNA. 2100356 6.42E−04 7.75 Down −1.70 −4.65 phospho!ipase C-like 1 (PLCL1), mRNA. 6770452 2.13E−04 7.52 Down −1.89 −4.80 PREDICTED: similar to hCGl 809904 (LOC391 761), mRNA. 5810768 1.78E−04 7.51 Down −1.36 −4.27 PREDICTED: hypothetical LOC646498 (LOC646498), mRNA. 6380364 4.53E−04 7.46 Down −1.27 −4.17 solute carrier family 7 (cationic amino acid transporter, y+ system), member 6 (SLC7A6), transcript variant 2, mRNA. 3940750 1.13E−04 7.42 Down −1.91 −4.81 PREDICTED: similar to hCG2024 106, transcript variant 1 (LOC100134648), mRNA. 7380161 2.21E−04 7.27 Down −3.11 −5.97 PREDICTED: neuroblastoma breakpoint family, member 1, transcript variant 16 (NBPF1), mRNA. 4220376 2.06E−04 7.23 Down −2.11 −4.97 absent in melanoma 1-like (AIM1L), mRNA. 5270603 4.32E−04 7.21 Down −1.50 −4.35 EPS8-like 2 (EPS8L2), mRNA. XM_943956 XM_943960 XM_943963 XM_943966 5050707 1.55E−04 7.19 Down −1.09 −3.93 angiopoietin-like 6 (ANGPTL6), mRNA. 4850110 4.74E−04 6.73 Down −2.09 −4.84 PREDICTED: hypothetical protein LOC645743 (LQC645743), mRNA. 5870091 6.14E−04 6.59 Down −2.03 −4.75 V-set and transmembrane domain containing 2A (V STM2A), mRNA. 460504 2.31E−04 6.50 Down −2.14 −4.84 chemokine binding protein 2 (CCBP2), mRNA. 6350445 6.13E−04 6.20 Down −1.44 −4.07 PREDICTED: similar to embigin homolog (LOC647121), mRNA. 3520114 9.96E−04 5.71 Down −1.32 −3.84 family with sequence similarity 19 (chemokine (C-C motitl-like), member A2 (FAM19A2), mRNA. 60735 5.14E−04 5.55 Down −2.64 −5.12 gamma-glutamyltransferase light chain 1 (GGTLC1), transcript variant A, mRNA. 4560088 6.52E−04 5.54 Down 1.03 −1.44 PREDICTED: hypothetical gene sDOWNported by AY007155 (LOC439949), mRNA. 4050132 6.18E−04 5.49 Down 0.55 −1.91 PREDICTED: similar to Iduronate 2- sulfatase precursor (Alpha-L-iduronate sulfate sulfatase) (Idursulfase) (LOC653157), mRNA. 21540441 6.28E−04 4.92 Down −1.75 −4.05 neurotrophin 3 (NTF3), mRNA. 6020553 8.44E−04 4.67 Down −1.17 −3.39 PREDICTED: similar to Neuronal acetylcholine receptor protein, beta-4 subunit precursor (LOC649686), mRNA. 2320593 3.73E−04 4.23 Down −0.61 −2.69 zinc finger protein 830 (ZNF830), mRNA. 6180543 6.30E−04 4.04 Down −0.51 −2.53 glycerol kinase 5 (putative) (GK5), mRNA. 3610154 1.53E−04 4.00 Down −0.69 −2.69 leucine-rich repeat-containing G protein- coDOWNled receptor 6 (LGR6), transcript variant 3, mRNA. 7210035 8.97E−04 3.60 Down 1.05 −0.80 small nucleolar RNA, C/D box 13 (SNORD13), small nucleolar RNA. 5260021 1.18E−04 3.44 Down −0.66 −2.44 cDNA FLJ11554 fis, clone HEMBA1003037 670279 1.34E−05 3.38 Down −0.49 −2.25 zinc finger protein 485 (ZNF485), mRNA.

Table Headers:

PROBEJD refers to the specific cDNA probe sequences used to detect the RNA transcript as described by the manufacturer of the Illumina Bead Chip version 12.4. P value refers to the t-test probability that the two groups of samples are actually derived from the same distribution of variance, A smaller value indicates a greater chance that the expression levels in two groups are significantly different in magnitude, FC (abs) refers to ‘fold change’ in absolute terms, i.e. corrected for the log 2 expression levels in the subsequent columns, which is the relative change in expression between groups. Con refers to the control group, and LRI refers to the lower respiratory infection group, where the values are normalized expression values expressed on log 2 scale. Thus, if Con is I and LR.1 is 3, then the difference is 2²=4 fold change (FC) DEFINITION is the formal name of the transcript as described in Genbank or Refseq, as related by the manufacturer's library file for the microarray. SYMBOL refers to the official gene symbol abbreviation, when available. The Genbank or Refseq numbers were obtained from NIH databases and the Illumina library file for the microarray. A given transcript can have multiple Genbank identifiers reflecting different studies that independently observed the sequence is a specific context.

Additional information on the biomarkers from Table 1, including the gene symbol and synonyms appear in Table 2 below,

TABLE 2 Def nitions, gene symbols and synonyms of biomarkers from Table 1. DEFINITION (SYMBOL) SYNONYMS Homo sapiens absent in melanoma 1-like (AIM1L), mRNA. FLJ10040; DKFZp434L1713; FLJ38020 Homo sapiens aminolevulinate, delta-, synthase 2 (ALAS2), nuclear ASB; XLSA; ANH1 gene encoding mitochondrial protein, transcript variant 3, mRNA. Homo sapiens angiopoietin-like 6 (ANGPTL6), mRNA. AGF; ARP5 Homo sapiens bactericidal/permeability-increasing protein (BPI), mRNA. Homo sapiens chemokine binding protein 2 (CCBP2), mRNA, D6; CCR9; MGC138250; MGC126678; CCR10; hD6; CMKBR9 Homo sapiens CD40 molecule, TNF receptor superfamily member 5 CDW40; TNFRSF5; p50; (CD40), transcript variant 2, mRNA. MGC9013; Bp50 Homo sapiens creatine kinase, mitochondrial 1B (CKMT1B), UMTCK; CKMT1; CKMT nuclear gene encoding mitochondrial protein, mRNA. Homo sapiens cathepsin G (CTSG), mRNA. M16117 Homo sapiens defensm, alpha 1B (DEFA1B), mRNA. Homo sapiens EPS8-like 2 (EPS8L2), mRNA. XM_943956 FLJ16738; EPS8R2; XM_943960 XM_943963 XM_943966 FLJ21935; MGC3088; FLJ22171; MGC126530 Homo sapiens family with sequence similarity 19 (ehemokine (C-C DKFZp781P0552; TAFA-2; motifs-like), member A2 (FAM19A2), mRNA. MGC42403; DKFZp761E1217; TAFA2 Homo sapiens family with sequence similarity 46, member C FLJ20202 (FAM46C), mRNA. i PREDICTED: Homo sapiens hypothetical protein FLJ23865 (FLJ23865), mRNA. Homo sapiens G antigen 12F (GAGE12F), mRNA. Homo sapiens gamma-glutamyltransferase light chain 1 (GGTLCl), (JJ831C21.2; MGC50550 transcript variant A, mRNA. Homo sapiens glycerol kinase 5 (putative) (GK5), mRNA. MGC40579: FLJ45739; FLJ33582 RST17329 Athersys RAGE library Homo sapiens cDNA, mRNA sequence Homo sapiens cDNAFLJ 11554 fis, clone HEMBA1 003037 yy43f04.s1 Scares melanocyte 2NbHM Homo sapiens cDNA clone IMAGE: 27401 5 3, mRNA sequence Homo sapiens primary neuroblastoma cDNA, clone: NbIal0527, full insert sequence pleekstrm homology domain interacting protein oo2Gc08.x1 Soares_NSF_F8_9W_OT_PA_P_S1 Homo sapiens cDNA clone IMAGE; 1566734 3, mRNA sequence Homo sapiens KIAA1045 (KIAA1045), mRNA, RP11-392A14.4; DKFZp434I2112 Homo sapiens kelch domain containing 1 (KLHDC1), mRNA, MST025; MGC126644; MGC126646 Homo sapiens lipocalin 2 (LCN2), mRNA. NGAL Homo sapiens leucine-i eh repeat-containing G protein-coupled VTS2063i; FLJ14471; receptor 6 (LGR6), transcript variant 3, mRNA. GPCR PREDICTED: Homo sapiens miscJRN A (LOG100128771), miscRNA, PREDICTED: Homo sapiens hypothetical protein LOC100129705 (LOG100129705), mRNA, PREDICTED: Homo sapiens similar to Fanconi anemia complementation group D2 protein (LOC100129929), mRNA. PREDICTED: Homo sapiens misc_RNA (LOCI 00133075), miscRNA. PREDICTED: Homo sapiens similar to hCG20241 06, transcript variant 1 (LOG100134648), mRNA. PREDICTED: Homo sapiens misc_RNA (LOCI00134669), miscRNA, PREDICTED: Homo sapiens hypothetical protein LOC339047, transcript variant 74 (LOC339047), mRNA. PREDICTED: Homo sapiens simiiar to hCGl 809904 (LOC391761), mRNA, PREDICTED: Homo sapiens similar to UDP-Gal:betaGIcNAc beta 1,3-galactosyltransferase, polypeptide 4 (LOC402377), mRNA. PREDICTED: Homo sapiens hypothetical gene supported by AY007155 (LOC439949), mRNA. PREDICTED: Homo sapiens similar to MHC class II antigen (LOC642073), mRNA. PREDICTED: Homo sapiens simiiar to hCGl 730248 (LOC643037), mRNA. PREDICTED: Homo sapiens region containing hypothetical protein LOC283970; similar to nuclear pore complex interacting protein, transcript variant 2 (LOC643943), mRNA. PREDICTED: Homo sapiens hypothetical protein LOC645743 (LOC645743), inRNA. PREDICTED; Homo sapiens similar to hCG1774990 (LOC646021), rnRNA. PREDICTED: Homo sapiens hypothetical LOC646498 (LOC646498), mRNA. PREDICTED: Homo sapiens similar to embigin homolog (LOC647121), mRNA. PREDICTED: Homo sapiens similar to Neuronal acetylcholine receptor protein, beta-4 subunit precursor (LOC649686), mRNA. PREDICTED: Homo sapiens similar to Iduronate 2-sulfatase precursor (Alpha-L-idiironate sulfate sulfatase) (idursulfase) (LOC653157). mRNA. PREDICTED; Homo sapiens similar to Neutrophil defensin ! precursor (HNP-1) (HP-1) (HP1) (Defensin, alpha 1) (LOC653600), mRNA. PREDICTED: Homo sapiens misc_RNA (LOC728522), miscRNA. PREDICTED: Homo sapiens similar to ring finger protein 18 (LOC732387), mRNA, Homo sapiens lactotransferrin (LTF), mRNA. HLF2; GIG12 Homo sapiens methyltransferase like 7B (METTL7B), mRNA. MGC 17301 Homo sapiens microRNA 940 (MIR940), microRNA. Homo sapiens myeloperoxidase (MPO), nuclear gene encoding mitochondrial protein, mRNA. Homo sapiens myelin transcription factor 1-like (MYlTL), mRNA. PREDICTED: Homo sapiens neuroblastoma breakpoint family, member 1, transcript variant 16 (NBPF1), mRNA. Homo sapiens neuroblastoma breakpoint family, member 7 ! (NBPF7), mRNA, Homo sapiens 5′-nueieo†idase domain containing 2 (NT5DC2), Ft J12442 mRNA. Homo sapiens neurotrophin 3 (NTF3), mRNA, HDNF; NGF-2; NT3; NGF2; MGC1 29711 Homo sapiens phospholipase C-iike 1 (PLCL1), mRNA. MGC138190; PLDL1; PLCE; PLCL; PLC-L; MGC1 26580 Homo sapiens processing of precursor 5, ribormclease P/iviRP HSPC004; RPP20; RPP2 subunit (S. cerevisiae) (POPS), transcript variant 2, mRNA. Homo sapiens PR domain containing 12 (PRDM12), mRNA. PFM9 Homo sapiens resistin (RETN), mRNA, XCP1; MGC1 26603; RSTN; RETN1; MGC1 26609; FIZZ3; ADSF Homo sapiens regulator of G-protein signaling 20 (RGS20), ZGAP1; RGSZ1 transcripi variant 1, mRNA. Homo sapiens ribosomal protein L10-like (RPL10L), mRNA. FLJ27353 Homo sapiens selenoprotein P, plasma, 1 (SEPPl), transcript vaiiant SeP; SELF 1, mRNA, Homo sapiens spliciag factor 1 (SF1), transcript variant 4, mRNA, DltS636; ZNF162; ZFM1 Homo sapiens SH3-domain GRB2-like (endophilin) interacting FI.J43054; protein 1 (SGIP1), mRNA. DKFZp761D221 ; FLJ33378; DKFZp686A16142 Homo sapiens SHC (Src homology 2 domain containing) SHCC; N-Shc; NSHC transforming protein 3 (SHC3), mRNA. Homo sapiens solute carrier family 22 (organic cation transporter), OCT2; MGC32628 member 2 (SLC22A2), mRNA. Homo sapiens solute carrier family 7 (cationic amino acid MPE16; CD98; 4F2LC; transporter, y+ system), member 5 (SLC7A5), mRNA. hLAT1; D16S469E; LAT1; E16 Homo sapiens solute carrier family 7 (cationic amino acid DKFZp686K15246; transporter, y+ system), member 6 (SLC7A6), transcript variant 2, KIAA0245; LAT3; LAT-2; mRNA. y + LAT-2 Homo sapiens small nucleolar RNA, C/D box 13 (SNORD13), small U13 nucleolar RNA. Homo sapiens synaptophysin-like 1 (SYPL1), transcript variant 1, H-SP1; SYPL mRNA. Homo sapiens tripartite motif-containing 34 (TRIM34), transcript RNF21; IFP1 variant 2, mRNA. Homo sapiens V-set and transmembrane domain containing 2A MGC33530; VSTM2 (VSTM2A), mRNA. Homo sapiens zinc finger protein 461 (ZNF461), mRNA. GIOT-1; ZNF461; GIOT1; MGC33911 Homo sapiens zinc finger protein 485 (ZNF485), mRNA. PREDICTED: Homo sapiens misc_RNA (ZNF788), miscRNA. Homo sapiens zinc finger protein 830 (ZNF830), mRNA. MGC20398 PREDICTED: Homo sapiens zinc finger protein 90 (HTF9) (ZNF90), mRNA. Homo sapiens alkaline phosphatase, liver/bone/kidney (ALPL), TNSALP; HOPS; transcript variant 1, mRNA. FLJ40094; AP-TNAP; TNAP; MGC161443 Homo sapiens mterleukin 8 receptor, beta (IL8RB), mRNA. CD182; CMKAR2; IL8RA; IL8R2; CXCR2; CDwl28b

Table Headers:

SYNONYMS are other recognized names for the gene or transcript.

GenBank and RefSEQ IDs for each of the gems from Tables 1 and 2 appear below:

Homo sapiens absent in melanoma 1-Like (AIM1L), mRNA: FLJ1004Q, DKFZp4 34L1713; FLJ3802G. GenBank/RefSeq IDs: AK000902 NM_001039775 AL451 139 CD628848 AK095339 CH471059 BC136870 DR004727 DA439029 AL137264, Homo sapiens aminolevulinate, delta-, synthase 2 (ALAS2), nuclear gene encoding mitochondrial protein, transcript variant 3, niRNA: AY532084 BP284609 BM677888 AK291589 Λ532085 AY532086 AYS32087 AY532088 AY532089 NM_001037967 CR609′889 NM_001037968 NM_000032 CR615092 AY532102 AY532101 Z83821 AY532100 CH471154 AK313118 AY532109 AY532108 AY532107 AY532081 AY532106 AY532080 AY532105 AY532083 AY532104 AY532082 AY532103 AY532097 AY532098 AK290565 AY532095 AY532096 CR593743 X56352 AY532099 AY190322 CR613185 AY532094 AY532093 CR626361 AY532092 AY532G91 X60364 CR591435 AA778169 AY532069 CR606333 AL020991 CR620984 BP233279 CR606670 AY532079 AY532Q78 CR608649 AY532077 AF068624 AY532076 AY532075 AY532074 AY532073 BC030230 AY532Q71 AY532072 AY532070 BQ182291 AF130113 Homo sapiens angiopoietin-like 6 (ANGPTL6), mRNA; CR591845 CH471106 AY358276 AB054064 BC1 42632 NM_03 1917 CR621970 CR617920 AC020931 AF230330. Homo sapiens bacterieidal/{circumflex over ( )}eriBeability-increasing protein (BPI), mRNA: CH471077 J04739BP306215 CQ800679 Y14219 Y14217 BC03223G Y14218 AL583962 Y14215 Y 14216 AK296568 AL359555 AF322588 Y 14220 AK3 15328 AI436120 Y14221 Y 14222 Y14223 AL499625 Y14228 Y14229 Y14224 Y14225 NM_i⁾0!725 Yl 4226 Y14227 AL39I692 DQ414688 BC040955. Homo sapiens chemokine binding protein 2 (CCBP2), mRNA: BC020558 U94888 BT006800 CH471055 AK3 13561 DQ229109 AC099329 DA853I59 AY262687 BC008816 BC018716 EU832737 AF481959 BC0U588 BC101629 Y12815 BC 112045 BE901 130 NM_001296 CR610139 BC01 1631. 1-iomo sapiens CD40 molecule, TNF receptor superfamily member 5 (CD40), transcript variant 2, mRNA: CH471077 NMJ 52854 CS097717 ΛK222896 BC012419 AB209660 DQ87 1604 AY225405 BM76 1221 CR605787 AL035662 EF064754 CS103051 DQ891804 BC064518 CR6 19622 CS103053 NM_001250 CS097719 CS097320 AY504960 AJ3G0189 DQ894988 BT0 19901 X60592 CS095651 CS097318 CR608994 CS095653. Homo sapiens creatine kinase, mitocliondrial 1B (CKMT1B), nuclear gene encoding mitochondrial protein, mRNA: BC121 002 BC121001 DQ893385 BC108652 AK294908 AK293685 AC011330 CR618017 AK293790 AK293961 NM_001015001 AK316319 AK3 16124 DQ896705 BC001926 CR605038 AK294735 BU674851 AK094322 AK223365 BM923431 J04469AK296271 AK294063 AK296472 NM_020990 CR599868 AK295776 AK3 16052 CR616544 CR597545 BT006628 BI1 18196 AK293939 AK308770 CR59951 1 BC006467. Homo sapiens cathepsin G (CTSG), mRNA: DQ893067 CR456807 BC014460 NM_001911 CR541704 AK225914 DQ896320 AL136018 AI272833 J04990CH471078. Homo sapiens defensm, alpha IB (DBFA1B), mRNA: AX405718 L12690 NM_004084 AF238378 AF200455 BC069423 X52053 AF233439 M26602 BC093791 DQ896798 DQ890546 DQ890545 NM_00ï042500 BC1 12188 M21130. Homo sapiens EPS8-like 2 (EPS8L2), mRNA. XM_943956 XM_943960 XM_943963 XM_943966: BC101481 BC080636 AK025824 AK094539 AK122903 AK294041 BC093878 AK2229G3 AK225311 AK122984 AK025588 NM_022772 BC002474 BC143242 AF318331 AP006621 AY074929 CH471158 AK027765. Homo sapiens family with sequence similarity 19 (chemokine (C-C motifj-like), member A2 (FAM19A2), mRNA: AL834160 AC078872 BC028403 CR749367 AC078789 CH471054 AC020647 AW161831 NM_1 78539 AY3251 15 AC137053 BC050347 BC040286 AK123580 AC1304 14. Homo sapiens family with sequence similarity 46, member C (FAM46C), mRNA: BC036516 AL046016 NM_017709 AK091327 CH471 122 BC131726 AL365331 AK000209 CD300120. PREDICTED: Homo sapiens hypothetical protein FLJ23865 (FLJ23865), mRNA: AK074445. Homo sapiens G antigen 12F (GAGE12F), mRNA: NC000023.10. Homo sapiens gamma-gluiamyitramferase light chain 1 (GGTLC1), transcript variant A, mRNA: NM_178311 NM_178312 CH471133 BC040904 I, 20491 L20492 AL133466. Homo sapiens glycerol kinase 5 (putative) (GK5), mRNA: DQ894800 BX648681 BC032470 BX648359 CH471052 NMJ301039547 AC108679 AK090901 BU628781 CR598125 AK310761 AK313792 DQ891607 AK130469 DR000158 AK127641. RST17329 Athersys RAGE Library Homo sapiens cDNA, mRNA sequence: Hs.134230. Homo sapiens cDNA FLJ1 1554 fis, clone HEMBA1003037: AK021616. yy43f04.sl Scares melanocyte 2NbHM Homo sapiens cDNA clone IMAGE: 27401 5 3, mRNA sequence: BC000393. Homo sapiens primary neuroblastoma cDNA, clone: Nblal0527, full insert sequence: AB074162. pleckstrin homology domain interacting protein: AJ303 102 AL049321 CH471051 BX537762 AF3 10250 BI548935 AL450327 BCl 37488 BC021905 ΛK 127816 BC008909 AK000712 ALl 61957 NM_0 17934 CR600369 BC036479 BC064611 BC081569 DQ924532 AK057039 DA5Q0781 AK075124 AL356776 BC144670. oo20c08.xl Soares_NSF_F8_9W_OT_PA_P_S1 Homo sapiens cDNA clone IMAGE: 1566734 3, niRNA sequence: HS.134230. Homo sapiens KIAA1045 (KIAA1045), mRNA: NM_0 15297. Homo sapiens kelch domain containing 1 (KLHDCl), mRNA: BCl 43597 AK127202 AK098735 BC143596 AL591767 NM_172193 BC101595 BC031270 BC101597 AF1 11806 AL833437 CH471078. Homo sapiens lipocalin 2 (LCN2), mRNA: AK316217 N79823 CR542092 C!-l47!090 BP272828 X99133 EU644752 X83006 S75256 BX644845 BC033089 NM_005564 CA454137 AL590708 AW778875 BM977724 AK301694 BF354583. Homo sapiens leueine-ricb repeat-containing G protein-coupled receptor 6 (LGR6), transcript variant 3, mRNA: NM_001 017404 BC047905 NM_001017403 AK123055 AK027377 BM699180 AF088074 CH471067 AY3581 19 AF190501 CQ84081 1 NM_021636 AB04940S BC038795 AB083616 AL356953. PREDICTED: Homo sapiens misc_RNA (LOC100128771), miscRNA: XR_037860.1. PREDICTED: Homo sapiens hypothetical protein LOG100129705 (LOG 100 129705), mRNA: XMJ)01723520.1, PREDICTED: Homo sapiens similar to Fanconi anemia complementation group D2 protein (LOC100129929), mRNA: XM_001732829.1 PREDICTED: Homo sapiens misc_RNA {LGC1OO133075), miscRNA: XR_039086.1. PREDICTED: Homo sapiens similar to hCG2024106, transcript variant I (LOCI00134648), mRNA: XM_001724649.1. PREDICTED: Homo sapiens misc_RNA (LOC100134669), miscRNA: XR_038059.1. PREDICTED: Homo sapiens hypothetical protein LOC339047, transcript variant 74 (LOC339047), mRNA: XM_001723375 NM_178541 AK124516 BC039707 AC137803 BC046145 BC008178 AC138969 AF229069 BC010188 AK126798 AC136619. PREDICTED: Homo sapiens similar to hCGl 809904 (LOC391761), mRNA: XM_373073.2 PREDICTED: Homo sapiens similar to UDP-Gal: betaGlcNAc beta 1,3- galactosyltransferase, polypeptide 4 (LOC402377), mRNA: AL599456 XR_079072 BP872983 BP872636 AL161911. PREDICTED: Homo sapiens hypothetical gene supported by AY0071 55 (LOC439949), mRNA: XM_001723825 XM_001 128367 AY007155 XM_0O1129241 AL158043. PREDICTED: Homo sapiens similar to MHC class II antigen (LOC642073), mRNA: XR_018080.2. PREDICTED: Homo sapiens similar to hCGl 730248 (LQC643037), mRNA: XM_926406 AADB02014322 AP000943 XM_936787. PREDICTED: Homo sapiens region containing hypothetical protein LOC283970; similar to nuclear pore complex interacting protein, transcript variant 2 (LOC643943), mRNA: XM_934575.1. PREDICTED: Homo sapiens hypothetical protein LOC645743 (LOC645743), mRNA: XM_928753.1. PREDICTED: Homo sapiens similar to hCG1774990 (LOC646021), mRNA: XM_001718652.1 PREDICTED: Homo sapiens hypothetical LOC646498 (LOC646498), inRNA: NM_001080528 AC135506 PREDICTED: Homo sapiens similar to embigin homolog (LOC647121), rnRNA: AL592494 AK128714 NR_003955 NM_198449 AK300860 AK304226 AC035145 CR625471 U52054 BC059398 CR621536 AC091833 CH471123 DC309453. PREDICTED: Homo sapiens similar to Neuronal acetylcholine receptor protein, beta-4 subunit precursor (LOC649686), mRNA: XM_938759.1. PREDICTED: Homo sapiens similar to Iduronate 2-suifatase precursor (Alpha-L- iduronate sulfate sulfatase) (Idursulfase) (LOC653157), mRNA: XM_926258.1. PREDIC′TED: Homo sapiens similar to Neutrophil defensin 1 precursor (HNP-1.) (HP-1) (HP1) (Defensin, alpha 1) (LOC653600), mRNA: XM_928349,1. PREDICTED: Homo sapiens misc_RNA (LOC728522), miscRNA: XR._015716.2. PREDICTED: Homo sapiens similar to ring finger protein 18 (LOC732387), mRNA: XM_94 1859.1 Homo sapiens lactotransferrin (LTF), mRNA: S52659 M83205 AY137470 M83202 AF332168 AK303889 CH471055 AF508798 U07643 AK316330 M73700 AK292813 DQ522304 U95626 DQ896102 BC015823 NMJ)0234 3 X52941 M18642 BC015822 DQ892855 AY493417 AY156717 AK303995 AY178998 BC022347 AY165046 EU779935 AK298035 AK093852 AY360320 M93150 X53961 AK290859 CD722125 AY875691 AC098613 Homo sapiens methyltransferase like 7B (METTL7B), mRNA: BC020509 NMJ52637 AY358508 AC009779 CH471054 CR595874 AK2901 12 Homo sapiens microRNA 940 (MIR94Q), microRNA: NRJ)30636. 1: NR_030636.1. Homo sapiens myeloperoxidase (MPO), nuclear gene encoding mitochondria! protein, mRNA: S56200 A08802 Z37728 M19507 J02694M17170 X15377 M17173 M17174 M17171 M17172 M19508 D14466 M17175 M17176 AC004687 BC130476 χ04876 DQ088846 CH471 109 χ64647 NM_000250. Homo sapiens myelin transcription factor 1-like (MYTIL), mRNA: BC031690 AL133024 BC042833 AB029029 AB073885 AC1 06046 BC071612 BF530661 AC008276 AC009232 BM7 15930 AF036943 BF439754 BC043230 AC093390 AC01 1301 AK299571 BC 137273 BCl 50281 BCl 37272 AK307797 AC009471 NM_015025 BC1091 13. PREDICTED: Homo sapiens neuroblastoma breakpoint family, member 1, transcript variant 16 (NBPFl), mRNA: NM_001101663 BC094705 AK055895 AL049742 AF379606 AK095030 AF379607 BC034418 CR599564 XM_(——)002346226 CR608846 BC169317 BC169318 BC169316 BC094841 DB300232 AF380582 NM_001037675 BC086308 AL1 17237 AF3 80580 NM_183372 BC063799 BX546486 BC027348 AL592284 NM_001 039703 AC026900 AK302413 AF379624 NM_015383 AF379626 AF379627 AF379628 AK294944 XM_001726946 AK092351 AF379620 AF379621 AF3 79622 AF3 79623 AK054850 AL359I76 XM_001717398 AF379615 AF379616 AF379613 AF131738 AF379614 AL355149 AF379619 AE1 38796 BX5 1 1041 AK290302 AF379617 AL050141 AF379618 BC021 111 AF379611 AF379612 AY894574 BC010124 AY894573 BCl 48331 AY894572 AL040349 AY894571 AY894570 BC071995 AY894579 AY894578 AY894577 AI,592307 AY894576 AY894575 AL137798 AK290142 AI865471 AF419617 XM_0017I. 5810 AF419616 AF419619 AF419618 AK095459 AF379632 AY894583 AF3 79631 A(.356004 AY894582 AF379634 AY894585 BCl 10431 AF379630 AY894581 AK125792 AY894580 AL139152 BCl 67783 AK294414 AF379635 NM_017940 AF420437 BQ890458 AK00Q726 BC136292 CR600619 AL954711 BC071723 AF161426 B{umlaut over (l)}552657 AB051480 CR610345 AK097180 BC023087 BX648497 AL022240 AL832622 AB033071 AY894561 BC013805 AY894563 AY894562 BC066930 AY894565 AY894567 AY894566 BX538005 AY894569 AY894568 BX842679 NM_173638 DQ786323 AK299360 NM_001170755 BC093404 AK{umlaut over (l)}23260, Homo sapiens neuroblastoma breakpoint family, member 7 (NBPF7), mRNA: NM_001047980.1. Homo sapiens S′-nucleotidase domain containing 2 (NT5DC2), mRNA: DA013090 DB265466 AK022504 CH471055 AW510639 BC047747 DR003312 AC1 12215 CR612874 BC014550 BM982658 NM_022908 AK092469 NM_001 134231 AF131781 AK023995. Homo sapiens neurotrophin 3 (NTP3), mRNA: AC137627 BC107075 X53-S3S CH471 116 AC007848 CN267386 AK293895 AW190653 CD672441 BC069773 BU939830 NM_002527 M37763 NM_001 102654 CR541906 M61180. Homo sapiens phospholipase C-Iike 1 (PLCL1), mRNA: D42108 AC092599 NM_(3011 14661 CH471063 ACI 09589 DA414853 AC013478 AC020719 BC101531 BP340710 BX537442 NM_006226 BC1 1 1985 DA193701 AGO11997 T87219 AK127514 AK302673. Homo sapiens processing of precursor 5, ribonuclease P/MRP subunit (S. cerevisiae) (POP5), transcript variant 2, mRNA: AJ306296 CB995722 AF070660 CH471054 AA918619 AC063943 BU155588 AK223206 BI668578 BC012505 NM_015918 AK303144 B{umlaut over (l)}549018 NM_J98202 CR625634 API 17232. Homo sapiens PR domain containing 12 (PRDM12), mRNA: NM_021619 CH471090 BC172255 AY004252 AL359092. Homo sapiens resistin (RETN), mRNA: NM_020415 BC069302 AC008763 BC101560 DQ301958 AF205952 AY207314 BC101554 AF352730 AF290874 AY359066 CH471139 AF32308L Homo sapiens regulator of G-protein signaling 20 (RGS20), transcript variant 1, mRNA: AF493940 AC100821 AC113194 AF060877 BC015614 AK094503 NM_G03702 AY046538 CR622266 BC063490 CR602987 CH471068 AF074979 NM_170587 BC031328 CR594448 BCG18618 AF366057 AF366056 AF366055 AP366054. Homo sapiens ribosomal protein L10-iike (RPL10L), mRNA: AK130863 NM_080746 AL591768 AB063608 BC0663I2 AM392934 AB063605 CH471078 BC014310. Homo sapiens selenoprotein P, plasma, 1 (SEPP1), transcript variant 1, mRNA: BC05I919 Z11793 AK094640 NM_005410 AC008945 AK225801 BC040075 NM_001093726 NM_o01085486 BC005244 AL833145 B1463468 AK096125 BC046152 AK311392 ALU365 19 BC015875 CR607609 CH471119 CR607105 DO022288 BC030009. Homo sapiens splicing factor 1 (SFl). transcript variant 4, mRNA: AP001462 AK301803 BC034451 BQ230035 CH471076 AK296237 AJ000OS2 EU832634 AJ000051 BC000773 L49345 BC069273 D26120 EU832710 BX095574 D26121 D26122 AK293753 BC008080 AK299705 BCOl 1657 BC008724 BC038446 BC032676 BC020217 NM_201995 NM_201997 Y08765 MM_201998 L49380 Y08766 CR600558 NM_004630 BU624935 CR615439. Homo sapiens SH3-domain GRB2-like (endopbilin) interacting protein 1 (SGiPl), mRNA: AK125044 BC040516 AL139147 NM_032291 AL354978 AL356913 DA801276 CH471059 BX640813 AB210039 CR622 14 1 AK298970 EU831934 ALi36561 AL391820 AK090697 AK29994I AM392887 CR749541 EU832029. Homo sapiens SHC (Src homology 2 domain containing) transforming protein 3 (SHC3), mRNA: D84361 BC026314 AL160054 DQ896663 AL353150 NM_016848 BX641I39, Homo sapiens solute carrier family 22 (organic cation transporter), member 2 (SLC22A2), mRNA: NM_003058.2 NMJ)03058 BC039899 CH471051 AL162582 AB075951 X98333 CR618035 AK290787 AJ251885 BC030978, Homo sapiens solute carrier family 7 (cationic amino acid transporter, y + system), member 5 (SLC7A5), mRNA: CH471114 ABO18542 NM_003486 CR625513 CR601601 AM182888 BC039692 BC042600 CR594130 AB017908 DQ896766 AF077866 DQ893338 ABO18009 AB023721 BC014177 AC126696 AF104032 M80244 BC1 14608. Homo sapiens solute carrier family 7 (cationic amino acid transporter, y + system), member 6 (SLC7A6), transcript variant 2, mRNA: CR623370 BC028216 AC020978 NM_001076785 DQ894203 CR601248 CR613948 DQ891023 CR749475 AK3 10866 AK311610 D87432 BP242589 BC1 13100 NM_003983 CH471092 CR606394 AK310602 CR592629 CR749291. Homo sapiens small nucleolar RNA, C/D box 13 (SNORD13), small micleoiai- RNA: NR_003041 AC091144, Homo sapiens synaptophysin-like 1 (SYPL1), transcript variant 1, mRNA: BG719851 CH471070 NMJ82715 AK292230 CB989012 BQ429369 X68194 BC020938 X61382 EU831812 NM_006754 S72481 AA969654 BC061887 BC016835 AC005095 CR616230 AK128279 CH236947 EU831889. Homo sapiens tripartite motif-containing 34 (TRIM34), transcript variant 2, mRNA: AK293295 NM_130390 BC1 56770 DA847894 BM989990 AK027664 AF220144 BG721109 AF220143 AC015691 NM_001003827 BG776117 BC140722 AK298301 NM_021616 CX760618 CR624250 AK023210 CR749260 AK3 16289 BC065575 AK290172 BC136871 NM_ 130389 AL583914 CH471064 BC047564 NM_001003818 NM_QQ1003819 NM_058166 AK316178 AB039903 AB039902 AK027876 AF220030 AB039904, Homo sapiens V-set and transmembrane domain containing 2A (VSTM2A), mRNA: NM_182546.2. Homo sapiens zinc finger protein 461 (ZNF461), mRNA: NM_153257 AB209279 AB021641 BC028631 AY329493 BX649031 AK292834 DQ894367 AK299370 AC074138 DQ891 185. Homo sapiens zinc finger protein 485 (7NF485), mRNA: CQ783574 BC014161 NMJ45312 AK074679 AL645634 CH471 160 BX648149 AK3 13328 AK299707. PREDICTED: Homo sapiens misc_RNA (ZNF788), miscRNA: XRJ)41527.1, Homo sapiens zinc finger protein 830 (ZNF830), mRNA: NM_052857.3. PREDICTED: Homo sapiens zinc finger protein 90 (HTF9) (ZNF90), mRNA: CR614976 NM_007138 CN386341 BC137211 CR593334 AC006539 CH471106 AK298173 AC011447 BX1 02781 M61870. Homo sapiens alkaline phosphatase, liver/bone/kidney (ALPL), transcript variant 1, mRNA: AL592309 ABO11406 BC066116 ABO12643 BC136325 NM_0G0478 NM_001 127501 AL359815 X53750 BC021289 AB209814 D87880 D87882 D87881 AK298085 M24429 BC126165 M24428 BC110909 D87877 D87887 D87876 CH471134 D87888 D87879 D8N89 D87878 D87883 AK3 12667 D87884 DA625627 D87875 D87885 D87874 D87886 DA631560 M24435 M24434 M24433 M24432 BC090861 M24431 M24430 AK293184 M24439 M24438 M24437 M24436 AK295608 X14174 AK097413. Homo sapiensinterleukin 8 receptor, beta (IL8RB). mRNA; U1 1869 DA670033 U11866 AK290906 DQ895671 NM_001168298 DA674925 i.19593 AB032733 AC124768 AB032734 U11873 U11872 DQ893661.

Example 2: Determination of Selected Biomarkers by Reverse Transcriptase (RT) and Droplet Digital Polymerase Chain Reaction (ddPCR)

In the prior example, 5 patients were categorized as lower respiratory infections (LRI), but analysis of the ease reports indicates that the patients with the lowest biomarker levels, especially DEFA1, were actually unlikely to have had a pulmonary infection, One patient clearly had a pulmonary embolism (PE) secondary to air travel, and another subject was actually a healthcare worker with a mild upper respiratory (UR) condition that could have been allergic.

In order to determine more fully whether the biomarkers had value in detecting pulmonary infections, 4 additional subjects were obtained, and they were compared with 3 subjects with known hernias, surgically confirmed, and 5 subjects presenting for coronary catheterization but no known pulmonary infection or distress. The 2 patients from Example 1 with PE and UR. condition were excluded, because they were not, in fact, suspected LRI/pneumonia, yielding 7 suspected LRI, and 8 control subjects,

Methods: The Tempus blood RNA preservative tubes were frozen at −80 C as in prior studies, and then thawed and total nucleic acid was isolated by the manufacturer's protocol. The total nucleic acids were treated with DNAse, as above, and the remaining RNA was concentrated and quantified as above. A specific amount of RNA (500 ng) was taken into a reverse transcriptase (RT) reaction using BioRad iScript (RNAse H+) with random hexamers primers, according to the manufacturer's procedure. From the RT reaction, the resulting cDNA was diluted 1:15 with, water to make a stock cDNA solution from each patient for further analysis. The stock cDNA from each patient was diluted 1:10 or 1:20 into the PGR reaction and <mixed with reagents for ddPCR. as specified by the manufacturer. In ddPCR, the RNA strands in aqueous solution are emulsified in oil diluent to create ‘droplets’ of extremely small volumes of aqueous solution such that, on average, only a single strand of any particular RNA will be contained within each droplet. Each droplet also contains polymerase, nucleotides, and the specific primers that are employed b quantify a specific RNA target (eg DEFA1) and a fluorochrome that detects the PCR amplimer (EvaGreen), thus making each droplet a small reaction vessel for PGR amplification. Any droplet that contain a DEI⁷A1 RNA transcript will produce a positive fluorescent droplet, while droplets that are negative for DEFA1 will produce little or no fluorescence. Thus, the number of positive droplets will be directly proportional to the absolute quantity of the RNA target in the sample and can be calculated using Bayesian statistics and a Poisson distribution.

The ddPCR analysis was conducted on the 7 suspected LRI, and 8 control subjects, using 3 biomarkers (DEFA1, ALPL, IL8RB) and one invariant control (ACTB). The ALPL and IL8RB markers are included here because the lungs can also be affected by biofilm infections, although that could not be determined in the present 7 suspected LRI subjects. Thus, DEFA1 is the exemplary biomarker that should be sensitive to a pulmonary infection. The absolute quantity of the transcripts was quantified by ddPCR and then corrected for any dilutions that were employed (10× or 20×), and then the levels of the biomarkers were expressed as a % of ACTB invariant control level for each sample.

Results: A s shown in FIG. 1, the level of the DEFA1 biomarker is markedly higher in suspected LRI/pneumo patients (n=7) versus non-LRI controls (n−8) (LRI=81.6%, (sem=42.4), vs Con=8.6¾(3.Q¾), t-test p<0.05). Likewise, the ALPL biomarker was also higher in LRI than controls, (LRI=2.7%(0.6%) vs Con=0.7%(0.09%), p<0.01). Neither IL8RB (L-R1===6.0%(1.5%) vs Con=<S.6%(1.0%), p>0.35), nor the combination of ALPL+IL8RB (LR1-8.7%(1.4%) v s Con=7.2%(1.1%), p>0.20) was significantly different between groups. Two of the subjects with suspected pneumonia showed relatively normal DEFA1 levels and so their charts were reviewed, In one case, it was discovered that the patient had been on antibiotics for 7 days prior to admission and blood sampling, and in the other case, the patient had pneumonitis due to amiodarone toxicity, with a cough, fever, and apparent infiltrates on X-ray, but showed a normal white blood cell count and had negative bacterial cultures, suggesting that the patient may not have had an active pulmonary infection at the time of sampling, although the clinical suspicion was reasonable.

Example 3: Other Embodiments of a Neutrophil Activation Test for Respiratory Infections

These further embodiments utilize the RNA and protein biomarkers disclosed in Examples 1 and 2 above, and disclose alternative methods by which they could be quantified in clinically relevant instances for humans and other living species.

Identification of RNA Biomarkers in Immune Cells without the Need for Lysis and RNA Purification.

There is a huge, worldwide, unmet medical need for a simple, rapid, inexpensive test that reports whether the patient's immune system is responding to a pathogen. In the U.S., some of this diagnostic need is fulfilled with advanced imaging tests, such as X-rays, CT, and MRI, but in developing countries, and rural areas of developed nations, diagnostic tools are limited to a thermometer, stethoscope, and possibly a white cell count.

A cell-based assay. In one embodiment of the present invention, termed ‘cell-based assay’, the said biomarkers would be quantitated on ceils, or cell fractions derived from the biological sample. The biological sample would include any samples previously described, such as blood, sputum, lavage, spinal fluid, etc, but the method of biomarker determination would not require the lysis of the cells contained therein. Rather, the cells within the sample would be captured by any of a variety of means known to persons skilled in the art, and then the RNA or protein levels of said biomarkers would be quantitated on the cells directly. In this method, the cells can be captured with, or without centrifugation, which has significant advantages because centrifugation is not always available in non-hospital settings. Further, the number of ceils required would be quite small, for instance in the range of 10,000 cells, which can be obtained from just microliters of blood. Venipuncture is painful and distressing, especially to children, and so a finger stick would be belter tolerated, but still provide an adequate sample of cells for analysis.

The overall design of the test is to conduct the cell-based assay on small volumes of blood, such as obtained from a venipuncture or finger stick. In one embodiment, the blood is drawn via capillary action into a flat chamber, which is separated into several smaller chambers. We disclose herein an exemplary method using just 2 cells types, neutrophils and T cells. Other types of cells can also be used. In one embodiment of the invention, each flow chamber is coated with specific antibodies to surface markers for neutrophils (CD 16b) or T cells (CD4) so that the desired cell is trapped by adhesion in that well [3; 4]. After an incubation period of about 10-20 minutes, the unbound cells are flushed away with buffer contained in the fluidic pack,

Biomarker detection. As described, any of a variety of conventional methods are used to immobilize cell-specific antibodies on a glass coverslip or other suitable surface to capture cells from whole blood or other relevant, biological samples. After washing away unbound cells, the bound cells are contacted with any of the analytical tools described for measuring the specific biomarkers, such as, for example, resistins (RSTN), defensins (DEFA1), and myeloperoxidases (MPQ). These analytical detection methods share the common trait that they bind to the target biomarker, and produce a detectable signal when bound to the biomarker.

Engineering: Any handheld automated microfluidic device and a smartphone based imager can be adapted for use in a method as described herein [5; 6], Suitable commercially available devices can also be used.

Bioinfonnatie: Once the handheld imager captures the detectable signal of said biomarkers in the cells, where for example the signal is DEFA1 mRNA level, it is then simple integration to compute the signal intensity per cell and ratio the level to the invariant control (e.g., ACTB) Because multiple channels can be used, or multiple signals on the same channel, it is clear that-multiple biomarkers can be quantitated on the same biological sample. In such a case, the biological markers could be combined to create a metric of neutrophil activation, such as, (RSTN+DEFA1+MPO)/ACTB=neutrophil activation level.

Alternatively or in addition, a ligase-based assay can be used to quantitate the RNA levels in suitable samples. Likewise, it is technically feasible to conduct RNA or cDNA sequencing reactions within cells, as described in the scientific literature.

Instead of, or in addition to, assays using RNA markers, either the level of protein or protein enzymatic activity can be used as the biomarker. For example, the cell-based assay described above can be adapted to detect RSTN or DEFA1 protein level, by a fluorescent antibody, or an enzymatic activity such MPO activity. Because separate chambers can be used for each type of reaction, one embodiment employs a hybrid test in which, for example, RSTN RNA is detected in one chamber, DEFA1 antigen in another, and MPO activity in a third. This can be accomplished without the need for obtaining additional clinical samples.

REFERENCES FOR BACKGROUND AND EXAMPLES

-   1. Lozano R Naghavi M Foreman K Lim S Sbibuya K Aboyans V Abraham I     Adair T Aggarwal R Ann S Y et al. 2012. Global and regional     mortality from 235 causes of death for 20 sage groups in 1991) and     2010: a systematic analysis for the Global Burden of Disease     Study 2010. Lancet 380(9859): 2095-2128. -   2. Toma Ï, Siegel M O, Keiser J, Yakovleva A, Kim A, Davenport L,     Devaney J, Hoffman B P, Aisubail R, Crandall K A et al. 2014.     Single-Molecule Long-Read 1.6$ Sequencing To Charaeterke the Lung     Mkrobiome from Mechanically Ventilated Patients with. Suspected     Pneumonia. J Clin Microbiol 52(11), 3913-3921. -   3. Sekine K. 2006. Panning of multiple subsets of leukocytes on     antibody-decorated poly(ethylene) glycol-coated glass slides.     Journal of immunological methods 313(1-2): 96-109. -   4. Sethu P, Moldawer L L, Mindrinos M N, Scumpia P O, Tannahill C L,     Wilhelmy J, Eiron P A, Brownstein W B H, Tompkins R G,     Toner M. 2006. Micro fluidic isolation of leukocytes from whole     blood for phenotype and gene expression analysis. Anal Chem 78(15):     5453-5461. -   5. Li B, Li L, Guar. A, Dong Q, Roan K, Hui R, Li Z. 2014. A     smartphone controlled handheld microfluidic liquid handling system.     Lab Chip 14(20): 4085-4092. -   6. Li Z. 2014. Miniature optofluidic darkfieid microscope for     biosensing. SPIE Uiirofast Nonlinear Imaging and Spectroscopy 98 15:     15. -   7. Aimansa R, Socias L, Sanchez-Gareia M, Martin-Loeches I, del Olmo     M, Andaluz-Ojeda D, Bobillo F, Rico L, Herrero A, Roig V et al 2012.     Critical COPD respiratory illness is linked to increased     transcriptomic activity of neutrophil proteases genes. BMC Res Notes     5: 401. -   8. Jendeberg A L, Stralin K, Hultgren 0. 2013, Antimicrobial peptide     plasma concentrations in patients with community-acquired pneumonia.     Scand J Infect Dis 45(6): 432-437. -   9. Berkestedt I, Herwald H, Ljunggren L, Nelson A,     Bodelsson M. 2010. Elevated plasma levels of antimicrobial     polypeptides in patients with severe sepsis. J Innate Immun 2(5):     478-482. -   10. Bostrom E A, Tarkowski A, Bokarewa M. 2009. Rests tin is stored     in neutrophil grannies being released upon challenge with     inflammatory stimuli. Biochim Biophys Acta 1793(12): 1894-1900. -   11. Macdonald S P, Stone S F, Neil C L, van Eeden P E, Fatovich D M,     Arendts G, Brown S G. 2014. Sustained elevation of resistin, NGAL     and 1L-8 are associated with severe sepsis/septic shock in the     emergency department, PLoS One 9(10): el 10678, -   12. Johansson L, Lirmer A, Sunden-Cullberg J, Haggar A, Herwald H,     Lore K, Treutiger C J, Norrby-Teglund A. 2009. Neutrophil-derived     hyperresistinemia in severe acute streptococcal infections. J     Immunol 183(6): 4047-4054. -   13. Kumari A M, Savolaiuen E R, Ukkola O H, Kesaniemi Y A, Jokela     M A. 2009. The expression of human resistin in different leucocyte     lineages is modulated by LPS and TNFalpha, Regul Pepi     157(1-3):_57-63. -   14. Lundergari C. Burke U, McCaffrey T. 2009. Prediction of bare     metal stent restenosis. U.S. Pat. No. 7,550,300. CapGen Sciences,     Inc., United States. -   15. Li B, Li Z. 2014. Handheld radiofluidic liquid handling system.     In US Patent Office. -   16. Li Z, Scherer A. 2014. Handheld low pressure mechanical cell     lysis device with single cell resolution. In US Patent Application.

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make changes and modificadoiis of the invention to adapt it to various usage and conditions and to utilize the present invention to its fullest extent. The preceding embodiments are to be construed as merely illustrative, and not limiting of the scope of the invention in any way whatsoever. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the compositions and methods of use thereof described herein. Such equivalents are considered b be within the scope of this invention and are covered by the following claims. Those skilled in the art will also recognize that all combinations of embodiments described herein are within the scope of the invention. 

1.-38. (canceled)
 39. A method of treating a lower respiratory infection, comprising: selecting a subject with said lower respiratory infection having an increase or decrease in an expression level of one or more biomarkers as compared to at least one invariant control marker, wherein an increase or decrease of at least three-fold in the level of expression of said one or more biomarkers as compared to the at least one invariant control marker is indicative of a lower respiratory infection; and treating said subject for a lower respiratory infection comprising administering antibiotics to said subject, administering antivirals to said subject, administering anti-inflammatories to said subject, or a combination thereof, wherein said one or more biomarkers is selected from the group consisting of Neutrophil defensin 1 precursor, Defensin alpha 1, LOC653600, defensin alpha 1B, Src homology 2 domain containing transforming protein 3, myeloperoxidase, lipocalin 2, cathepsin G, bactericidal/permeability-increasing protein, lactotransferrin (LTF), solute carrier family 22 member 2, methyltransferase like 7B, resistin, zinc finger protein 90, family with sequence similarity 46 member C, solute carrier family 7 member 5, aminolevulinate delta-synthase 2, 5′-nucleotidase domain containing 2, LOC646021, G antigen 12F, LOC100133075, hypothetical protein FLJ23865, RST17329 Athersys RAGE Library cDNA, hypothetical protein LOC339047 transcript variant 74, CD40 molecule TNF receptor superfamily member 5 transcript variant 2, splicing factor 1 transcript variant 4, synaptophysin-like 1 transcript variant 1, selenoprotein P plasma 1 transcript variant 1, cDNA DKFZp779F0411, LOC643037, SH3-domain GRB2-like (endophilin) interacting protein 1, microRNA 940, PR domain containing 12, IMAGE clone 15667343, LOC100128771, LOC732387, region containing hypothetical protein LOC283970 transcript variant 2 LOC643943, hypothetical protein LOC100129705, LOC728522, regulator of G-protein signaling 20 transcript variant 1, kelch domain containing 1, LOC100134669, tripartite motif-containing 34 transcript variant 2, ribosomal protein L10-like, LOC100129929, LOC402377, LOC642073, zinc finger protein 461, creatine kinase mitochondrial 1B, yy43f04.s1 Soares melanocyte 2NbHM cDNA clone, KIAA1045, ZNF788, primary neuroblastoma clone:Nbla10527, processing of precursor 5 ribonuclease P/MRP subunit transcript variant 2, myelin transcription factor 1-like, neuroblastoma breakpoint family member 7, phospholipase C-like 1, LOC391761, LOC646498, solute carrier family 7 member 6 transcript variant 2, LOC100134648, neuroblastoma breakpoint family member 1 transcript variant 16, absent in melanoma 1-like, EPS8-like 2, angiopoietin-like 6, LOC645743, V-set and transmembrane domain containing 2A, chemokine binding protein 2, LOC647121, family with sequence similarity 19 (chemokine (C-C motif)-like) member A2, gamma-glutamyltransferase light chain 1 transcript variant A, LOC439949, LOC653157, neurotrophin 3, LOC649686, zinc finger protein 830 (ZNF830), glycerol kinase 5, leucine-rich repeat-containing G protein receptor 6 transcript variant 3, small nucleolar RNA C/D box 13, cDNA FLJ11554 fis clone HEMBA1003037, zinc finger protein 485, alkaline phosphatase liver isoform (ALPL), and interleukin-8 receptor beta (IL8RB).
 40. The method of claim 39, wherein said increase or decrease in an expression level of one or more biomarkers as compared to at least one invariant control marker is determined by a process comprising: obtaining a biological sample from said subject; detecting expression levels of said one or more biomarkers in the biological sample; and determining said increase or decrease in the expression levels of said one or more biomarkers by comparing the expression levels of said one or more biomarkers to said at least one invariant control marker wherein an increase or decrease of at least three-fold in the level of expression of said one or more biomarkers as compared to said at least one invariant control marker is indicative of said lower respiratory infection.
 41. The method of claim 40, wherein said detecting expression levels of one or more biomarkers comprises detecting expression levels of at least three biomarkers, and wherein determining the expression levels of said one or more biomarkers comprises determining the expression levels of said at least three biomarkers by comparing the expression levels of said at least three biomarkers to at least one invariant control marker wherein an increase or decrease in the level of expression of said at least three biomarkers as compared to the at least one invariant control marker is indicative of a lower respiratory infection.
 42. The method of claim 40, further comprising calculating a biomarker infection score from said increase or decrease in the expression levels of said one or more biomarkers and comparing said biomarker infection score to a control score.
 43. The method of claim 40, wherein said determining an increase or decrease in the expression levels of said one or more biomarkers comprises using a multivariate prediction model to determine if a pattern of expression of said one or more biomarkers is indicative of a lower respiratory infection.
 44. The method of claim 40, wherein said biological sample is a blood sample.
 45. The method of claim 44, wherein said obtaining a biological sample further comprises isolating immune cells from said blood sample.
 46. The method of claim 45, wherein said immune cells are neutrophils, T-cells, or a combination thereof.
 47. The method of claim 40, wherein detecting expression levels of one or more biomarkers comprises measuring RNA levels of said one or more biomarkers.
 48. The method of claim 40, wherein measuring RNA levels comprises using fluorescently-labeled probes complementary to said one or more biomarkers, a ligase-based assay, reverse transcriptase and polymerase chain reaction, RNA sequencing or cDNA microarray.
 49. The method of claim 39, wherein said one or more biomarkers in the biological sample are selected from the group consisting of bactericidal/permeability-increasing protein, myeloperoxidase, resistin, G antigen 12F, CD40 molecule TNF receptor superfamily member 5 transcript variant 2, and splicing factor 1 transcript variant
 4. 50. The method of claim 39, wherein said one or more biomarkers in the biological sample are defensin alpha-1, alkaline phosphatase liver isoform (ALPL), and interleukin-8 receptor beta (IL8RB).
 51. The method of claim 39, wherein said at least one invariant control marker is selected from the group consisting of Spi-B transcription factor, protein phosphatase 1 regulatory subunit 21 (PPP1R21, KLRAQ1), mitogen-activated protein kinase kinase kinase 7 (MAP3K7, TAK1), olfactory receptor family 51 subfamily member 1 (OR51M1), BCL2 antagonist/killer (BAK1), adenosine deaminase, RNA-specific (ADAR1), and actin-beta (ACTB).
 52. A kit for use in diagnosing a lower respiratory infection in a subject comprising: a plurality of agents that specifically bind one or more biomarkers selected from the group consisting of Neutrophil defensin 1 precursor, Defensin alpha 1, LOC653600, defensin alpha 1B, Src homology 2 domain containing transforming protein 3, myeloperoxidase, lipocalin 2, cathepsin G, bactericidal/permeability-increasing protein, lactotransferrin (LTF), solute carrier family 22 member 2, methyltransferase like 7B, resistin, zinc finger protein 90, family with sequence similarity 46 member C, solute carrier family 7 member 5, aminolevulinate delta-synthase 2, 5′-nucleotidase domain containing 2, LOC646021, G antigen 12F, LOC100133075, hypothetical protein FLJ23865, RST17329 Athersys RAGE Library cDNA, hypothetical protein LOC339047 transcript variant 74, CD40 molecule TNF receptor superfamily member 5 transcript variant 2, splicing factor 1 transcript variant 4, synaptophysin-like 1 transcript variant 1, selenoprotein P plasma 1 transcript variant 1, cDNA DKFZp779F0411, LOC643037, SH3-domain GRB2-like (endophilin) interacting protein 1, microRNA 940, PR domain containing 12, IMAGE clone 15667343, LOC100128771, LOC732387, region containing hypothetical protein LOC283970 transcript variant 2 LOC643943, hypothetical protein LOC100129705, LOC728522, regulator of G-protein signaling 20 transcript variant 1, kelch domain containing 1, LOC100134669, tripartite motif-containing 34 transcript variant 2, ribosomal protein L10-like, LOC100129929, LOC402377, LOC642073, zinc finger protein 461, creatine kinase mitochondrial 1B, yy43f04.s1 Soares melanocyte 2NbHM cDNA clone, KIAA1045, ZNF788, primary neuroblastoma clone:Nbla10527, processing of precursor 5 ribonuclease P/MRP subunit transcript variant 2, myelin transcription factor 1-like, neuroblastoma breakpoint family member 7, phospholipase C-like 1, LOC391761, LOC646498, solute carrier family 7 member 6 transcript variant 2, LOC100134648, neuroblastoma breakpoint family member 1 transcript variant 16, absent in melanoma 1-like, EPS8-like 2, angiopoietin-like 6, LOC645743, V-set and transmembrane domain containing 2A, chemokine binding protein 2, LOC647121, family with sequence similarity 19 (chemokine (C-C motif)-like) member A2, gamma-glutamyltransferase light chain 1 transcript variant A, LOC439949, LOC653157, neurotrophin 3, LOC649686, zinc finger protein 830 (ZNF830), glycerol kinase 5, leucine-rich repeat-containing G protein receptor 6 transcript variant 3, small nucleolar RNA C/D box 13, cDNA FLJ11554 fis clone HEMBA1003037, zinc finger protein 485, alkaline phosphatase liver isoform (ALPL), and interleukin-8 receptor beta (IL8RB); an agent that specifically binds to at least one invariant control marker; a container for housing said plurality of agents and said agent; and instructions for use of said plurality of agents and said agent for determining an increase or decrease in the expression levels of said one or more biomarkers by comparing the expression levels of said one or more biomarkers to said at least one invariant control marker wherein an increase or decrease in the level of expression of said one or more biomarkers as compared to the at least one invariant control marker is indicative of a lower respiratory infection.
 53. The kit of claim 52, wherein said plurality of agents and said agent are polynucleotides that specifically bind to RNA transcripts of the one or more biomarkers and of the at least one invariant control marker.
 54. The kit of claim 52, wherein the polynucleotides are labeled with a detectable marker.
 55. The kit of claim 52, wherein said plurality of agents and said agent are polynucleotides that amplify polynucleotides encoding the one or more biomarkers and the at least one invariant control marker.
 56. The kit of claim 52, further comprising instructions for calculating a biomarker infection score from said increase or decrease in the expression levels of said one or more biomarkers and comparing said biomarker infection score to a control score.
 57. The kit of claim 52, further comprising instructions for determining an increase or decrease in the expression levels of said one or more biomarkers by using a multivariate prediction model to determine if a pattern of expression of said one or more biomarkers is indicative of a lower respiratory infection.
 58. The kit of claim 52, wherein said plurality of agents that specifically bind to one or more biomarkers bind to one or more biomarkers selected from the group consisting of bactericidal/permeability-increasing protein, myeloperoxidase, resistin, G antigen 12F, CD40 molecule TNF receptor superfamily member 5 transcript variant 2, and splicing factor 1 transcript variant
 4. 59. The kit of claim 52, wherein said plurality of agents that specifically bind to one or more biomarkers bind to defensin alpha-1, alkaline phosphatase liver isoform (ALPL), and interleukin-8 receptor beta (IL8RB).
 60. The kit of claim 52, wherein said agent that specifically binds to at least one invariant control marker selected from the group consisting of actin-beta (ACTB), Spi-B transcription factor, protein phosphatase 1 regulatory subunit 21 (PPP1R21, KLRAQ1), mitogen-activated protein kinase kinase kinase 7 (MAP3K7, TAK1), olfactory receptor family 51 subfamily member 1 (OR51M1), BCL2 antagonist/killer (BAK1), and adenosine deaminase, RNA-specific (ADAR1).
 61. The kit of claim 52, further comprising reagents for fluorescently-labeled probes complementary to the said biomarkers, a ligase-based assay, reverse transcriptase and polymerase chain reaction, RNA sequencing or cDNA microarray.
 62. The kit of claim 52, wherein said plurality of agents that specifically bind one or more biomarkers specifically bind to at least three biomarkers, and wherein said instructions for use of said plurality of agents and said agent for determining an increase or decrease in the expression levels of said one or more biomarkers comprise instructions for use of said plurality of agents and said agent for determining an increase or decrease in the expression levels of said at least three biomarkers by comparing the expression levels of said at least three biomarkers to said at least one invariant control marker wherein an increase or decrease in the level of expression of said at least three biomarkers as compared to the at least one invariant control marker is indicative of a lower respiratory infection. 